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ABSTRACT 
 
Introduction: 
 
The role of fibroblast growth factor-2 (FGF-2) on colorectal cancer (CRC) cells 
exposed to chemotherapy has not been studied extensively.  This thesis investigated 
whether FGF-2 mediates chemoresistance in primary (SW480) and metastatic 
(SW620) colon adenocarcinoma cell lines.  
 
 
Methods:  
 
Proliferation assays were used to assess the response of SW480 and SW620 colon 
cancer cell lines to varying concentrations of FGF-2 and to optimise the dose of 5-
FU at which 50% cell death was observed. Cell survival assays were performed 
following 96 hours exposure to 5-FU ± FGF-2. Levels of chemotherapy induced 
apoptosis were determined using Caspase-3/7 assay. Expression of anti-apoptotic 
proteins (Bcl-2 and Bcl-XL) and FGFRs at both protein and gene level were 
determined to see if these contributed to the difference in chemoprotection observed. 
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Results:  
 
At 0.25 ng/ml, FGF-2 did not affect proliferation in either cell lines. 25µM of 5-FU 
resulted in 50% kill in both cell lines. Significant cell survival was observed when 
FGF-2 (0.25 ng/ml) pre-treated SW620 cells were exposed to 5-FU (25 µM) 
compared to cells exposed to 5-FU alone (81% vs 60%, p=0.015). This 
chemoresistance was associated with attenuation of cellular apoptosis (p=0.04) with 
no significant change in expression of Bcl-2 and Bcl-XL at gene or protein level. This 
survival advantage was not seen in SW480 cells (59% vs 55%, p=0.35). There were 
no observed differences in the expression of FGFR1-4 in either cell lines. 
 
 
Conclusion: 
 
FGF-2 offers chemoresistance to SW620 and not to SW480 cells exposed to 5-FU. 
Both cell lines expressed fgf2 and fgfr1-4 genes, suggesting that fgfr expression does 
not account for the difference in chemoresistance. FGF-2 offered protection by 
causing significant reduction in chemotherapy induced apoptosis in SW620 colon 
cancer cell line; however this was not due to increased expression of anti-apoptotic 
proteins. The molecular mechanisms for this selective chemoprotection need to be 
investigated further.  
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1.1Colorectal Cancer 
 
 
1.1.1 Incidence  
 
Colorectal cancer (CRC) is a commonly diagnosed cancer in both men and women. 
In the United States alone an estimated 153,760 new cases will be diagnosed and 
52,180 deaths from CRC will occur in 2007 (1). There are approximately 35,000 new 
cases of CRC diagnosed in the UK each year: around two-thirds (21,167) in the colon 
and one-third (13,389) in the rectum.  It is the third most common cancer in the 
United Kingdom after breast and lung cancer (2-5). 
 
1.1.2 Age & Sex Distribution 
 
The occurrence of large bowel cancer is strongly related to age, with 83% of cases 
arising in people aged 60 or older (2-5). In England and Wales, the lifetime risk for 
men of being diagnosed with CRC is estimated to be 1 in 18 and for women 1 in 20 
(6). At present, CRC is the second most common cancer in women after breast cancer 
whereas in men it ranks third after prostate and lung cancer. The crude incidence rates 
of colon cancer are similar for men and women in the UK but those for rectal cancer 
are higher in men. When the rates are age-standardized, male rates are higher than 
female rates for both colon and rectal cancer. 
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1.1.3 Survival 
There have been similar and significant improvements in survival for both colon and 
rectal cancer over the last 25 years. Five-year relative survival rates for both male and 
female colon and rectal cancer have doubled between the early 1970s and the late 
1990s. These improvements are likely to be the result of earlier diagnosis and better 
treatment however the overall picture is still disappointing. There is a difference 
around 5%-9% between affluent and deprived social groups in five-year relative 
survival (7). Overall 5-year survival rates for CRC is about 47% in males and 48% in 
women but this varies from approximately 83% for Dukes A, 64% for Dukes B, 38% 
for Dukes C and 3% for Dukes D (8). However 5 year survival rates for patients with 
liver metastases who are suitable for liver surgery varies from 25-40% (9-12). In 
addition to the stage of the disease at diagnosis, those patients who present as an 
emergency with evidence of blood loss, obstruction or perforation; or those who 
develop anastomotic dehiscence have higher postoperative mortality rates and poorer 
cancer specific survival (13).  
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1.2 Colorectal cancer and Genetics 
1.2.1 Familial Colorectal cancers 
 
Nearly 80% of patients with CRC have sporadic disease, while the remaining 20% of 
patients have a strong family history that suggests a genetic contribution or common 
exposures among family members or a combination of both. Individuals with two or 
more first degree relatives with CRC, one of whom is aged under 60 or one relative 
with CRC under the age of 45, have a moderate risk of developing colon cancer. 
Their risk is greater than five times the risk to an individual of the same age in the 
general population without a family history (14; 15). The guidelines devised by St. 
Mark’s Hospital, London for referral of patients to the family cancer clinic are 
summarised in Table 1.1. The two most common inherited conditions associated with 
an increased risk of CRC are Familial Adenomatous Polyposis Coli (FAP) and 
hereditary non-polyposis colorectal cancer (HNPCC), (also called Lynch Syndrome 
Type I and Type II). 
 
Familial Adenomatous Polyposis (FAP) 
FAP accounts for approximately 1% of cases of CRC with a prevalence of 
approximately 1 in 7500 (16). It is an autosomal dominant condition caused by 
mutations in the adenomatous polyposis coli (APC) gene and characterised by the 
development of multiple adenomatous colorectal polyps and the subsequent 
development of one or more CRC’s (17). 
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No. of affected 
people in the 
family related to 
the proband 
Relation-           
ship  to 
the 
proband 
Type       
of    
Cancer 
Age of 
Relative 
Risk 
group 
Screen
-ing 
needed 
Types of  Screening To be seen at 
Specialist  
Genetic clinic 
  1 1  FDR CRC >45 Low No None No- Reassure. 
Advice on 
diet, bowel    
awareness 
 1  FDR CRC <45 High/ 
Mod 
Yes 1st colonoscopy at 45 yr 
or when patient presents 
(whichever is later). 
Repeat 5 yearly  till 75 yr 
In some cases 
  2 2 SDRs CRC  Low No None No- Reassure. 
Advice on 
diet, bowel   
awareness 
 1FDR     
+                
1SDR 
(on same 
side       
of 
family) 
CRC  Low/ 
Mod 
Yes Single colonoscopy at 55 
yr or when patient 
presents (whichever is 
later) 
No 
 2 FDRs  
CRC 
Age<60 
 
 
Age>60 
High/  
Mod 
 
Low/                
Mod 
Yes 
 
 
Yes 
1st colonoscopy at 45 yr 
or when patient presents 
(whichever is later). 
Repeat 5 yearly  till 75 yr 
 
Single colonoscopy at 55 
yr or when patient 
presents (whichever is 
later) 
Yes 
 Both      
parents 
affected 
CRC  Low/  
Mod 
Yes Single colonoscopy at 55 
yr or when patient 
presents (whichever is 
later) 
No 
   3  CRC 
CRC  
or 
HRC 
 High/ 
Mod 
 Yes 1st colonoscopy at 45 yr 
or when patient presents 
(whichever is later). 
Repeat 5 yearly  till 75 yr 
Yes 
A family H/O 
known hereditary 
CRC syndrome, 
or multiple CR 
polyps e.g. FAP, 
AFAP, PJS, FJP 
or HNPCC (by 
fulfilment of 
modified 
Amsterdam 
criteria) 
    High              Yes                        FAP, PJS, &FJP: As per  
St. Mark’s polyposis 
registry protocol               
AFAP: On an individual 
basis.   HNPCC: 
1stcolonoscopy at 25 yr or  
when patient presents 
(whichever is later) and 
then repeated 2 yearly to 
75 yr 
Pelvic/Renal/Stomach 
surveillance as 
appropriate 
Yes 
Table 1.1 Guidelines for referral to the Family Cancer Clinic at St. Mark’s 
Hospital, London. Abbreviations- FDR: First degree relative, SDR: second degree 
relative, HNPCC: Hereditary Non Polyposis Colorectal Cancer, HRC: HNPCC 
related cancer, FAP: Familial adenomatous polyposis coli, AFAP: Attenuated FAP, 
PJS: Peutz Jeger’s syndrome, FJP: Familial juvenile polyposis. 
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APC is a tumour suppressor gene. One of the many roles of APC is regulating cell 
replication. Most mutations in the APC gene result in a short, non-functioning protein 
that disrupts the balance of cell proliferation and cell death. Hundreds of APC 
mutations have been identified. Research has shown that there is a link between the 
site of the APC mutation and the number and site of polyps that a patient will have. 
This is known as the 'genotype-phenotype' correlation. Gardner’s syndrome is a 
variant of FAP and individuals with this syndrome develop adenomatous polyp 
throughout the gastrointestinal tract accompanied by extracolonic manifestations 
including peri-ampullary adenomas, papillary carcinoma of the thyroid, 
hepatoblastoma, osteomas of the mandible and skull, epidermal cysts and desmoid 
tumours.  Mutated APC has been linked to chromosomal instability, where 
aneuploidy (an abnormal number of chromosomes) is seen in cells. Chromosomal 
instability is thought to occur in 85 per cent of all CRC cases.  
These polyps are histologically identical to those found in patients with non-
hereditary polyps and the distribution of the cancers that invariably develop is similar 
to those with sporadic cancer (18). Polyps first appear during the second decade of 
life with symptoms becoming apparent by the third and fourth decades. The average 
age at diagnosis of cancer is 39 (19). The penetrance of FAP is over 80% and not 
100% as initially thought (20). This is due to the recognition of an attenuated form of 
FAP (attenuated polyposis coli- AAPC) where patients have fewer polyps that are 
found more proximally in the colon compared with sporadic cancer and a reduced 
risk of cancer compared with FAP (21). 
Individuals at risk of FAP determined either by a positive family history or on the 
basis of APC mutation analysis should be offered annual sigmoidoscopy by age 13 
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for the first few years followed by annual colonoscopy with dye spray. The main 
treatment options for FAP once polyposis is established are (1) proctocolectomy with 
ileostomy or ileoanal pouch reconstruction and (2) colectomy with ileorectal 
anastomosis. While the former procedures are associated with greater operative 
morbidity and less satisfactory functional results, patients undergoing the latter 
procedure require regular lifelong sigmoidoscopic surveillance of the rectum 
postoperatively because of the risk of developing cancer in the retained rectum 
(22;23). As FAP patients are also at a risk of developing duodenal adenomas and 
cancers, regular gastrointestinal endoscopy surveillance is warranted where 
appropriate. 
 
 
Hereditary non-polyposis colorectal cancer (HNPCC) 
HNPCC accounts for approximately 1-2% CRC cases. It is also an autosomal 
dominant condition caused by a mismatch repair gene mutation. These mutations also 
predispose patients to extracolonic tumours predominantly endometrial but also 
gastric, ovarian, genitourinary, small bowel or biliary tract. The Revised Amsterdam 
criteria are considered gold standard for diagnosing whether a family has HNPCC 
and classify HNPCC families as (1) at least three relatives with HNPCC associated 
cancer (colorectal, endometrial, small bowel, ureter or renal pelvis) one of whom 
should be a first degree relative of the other two (2) at least two consecutive 
generations should be affected or (3) at least one individual should be diagnosed 
before the age of 50 (24). A second set of criteria called the Bethesda criteria are used 
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to determine whether a person with CRC should have his or her cancer tested for 
genetic changes that are seen in HNPCC, although the majority of the people who 
meet these criteria do not have HNPCC. These criteria include at least one of the 
following: the person is younger than 50 years; the person has or had another cancer 
(endometrial, stomach, pancreas, ovary, kidney or ureters, bile duct) that is associated 
with HNPCC; the person is younger than 60 years and the cancer has certain 
characteristics seen with HNPCC when viewed under the microscope; a first degree 
relative has been diagnosed with CRC and non CRC often seen in HNPCC carriers 
(endometrial, stomach, pancreas, ovary, kidney or ureters, bile duct) and one of these 
occurs when the person was younger than 50 years; and the person has two or more 
second degree relatives who had CRC and an HNPCC related tumour at any age.  
Identified individuals carrying the mutation can be offered regular endoscopic 
screening whilst those demonstrated not to carry the mutation can be spared invasive 
investigations. When a mismatch repair gene mutation is identified, the risk of the 
carrier developing colorectal cancer by the age of 70 years is over 70% for men and 
40% for women. A significant proportion of these patients will have developed their 
cancer before the age of 35 years. Female mismatch repair mutation carriers have a 
risk of gynaecological malignancy equivalent to their risk of colorectal cancer 
(22;25). Not every one who inherits the gene will develop a malignancy. There are 
environmental factors and other genetic factors also involved in the development of 
cancer, which are not yet fully understood e.g. diet. Men who inherit a faulty gene 
have a 91% risk of developing a CRC. Women who inherit a faulty gene have a 61% 
risk of developing a CRC and a 43% risk of developing uterine cancer. 
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1.3 Pathological Staging 
The gold standard reference for cancer staging continues to be histopathological 
assessment of the excised colorectal specimen. Various staging systems have been 
used for CRC; the most widely used being that proposed by Cuthbert Dukes in 1932 
(26). This system was originally described for rectal carcinomas and is now also 
applied to carcinomas of the colon. Stage A tumors were defined as those limited to 
the wall (not extending beyond muscularis propria), stage B as those extending 
through the wall (into subserosa and/or serosa, or extra-rectal tissues), and stage C as 
those having lymph node metastasis. The stage C was later subdivided by Dukes 
himself into C1 when only perirectal nodes were positive and C2 when nodes at the 
point of mesenteric blood vessel ligature (called apical nodes) were involved (27).  
The stage D was added still later and was characterized by presence of tumor beyond 
the limits of surgical resection (28).  
The Astler-Coller system includes tumour penetration and nodal involvement, and its 
modified version also incorporates tumour adherence to the surrounding structures 
(Table 1.2) (29). Surgeons and oncologists are increasingly using the unified TNM 
(Tumour-Node-Metastasis) stage system of the UICC (Union International Contre le 
Cancer) and AJCC (American Joint Committee on Cancer), as it separately identifies 
each component of a tumour’s risk; tumour stage (T), node stage (N) and metastasis 
(M) (30) (Table 1.3). 
 
Many other staging systems have been proposed trying to define a scheme which is 
more predictive including the Gunderson-Sosin modification of the Astler-Coller 
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system that subclassifies B2 and C2 tumours into those with microscopic (B2m or 
C2m) and gross (B2m+g or C2m+g) invasion of tumour through the bowel wall (31). 
The Gastrointestinal Tumour Study Group (GITSG) classification uses the number of 
nodes (1-4 and >4) involved to separate stages C1 and C2, respectively and the 
classification by Jass et al. uses absence or presence of transmural penetration, 
pushing or infiltrative margin of primary tumour, absence or presence of conspicuous 
peritumoural lymphocytic infiltrate, and number of positive nodes for a mathematical 
stratification (32;33).  
 
Dukes AC MAC TNM Description 
A A 
B1 
A 
B1 
T1N0 
T2N0 
Node negative; limited to mucosa 
Node negative; penetration into submucosa, not 
through muscularis propria 
B B2 B2 
 
B3 
T3N0 
 
T4N0 
Node negative; penetration through muscularis 
propria 
Node negative; penetration through muscularis 
propria, adherence to or invasion of surrounding 
organs or structures 
C C1 
C2 
C1 
C2 
 
 
 
C3 
T1-2N1 
T3N1 
 
 
 
T4N1 
Node positive; limited to bowel wall 
Node positive; penetration through muscularis 
propria 
Node positive; penetration through muscularis 
propria and adherence to or invasion of surrounding 
organs or structures 
 
Table 1.2 Staging systems of Colorectal Cancer compared 
AC= Astler Coller; MAC= Modified Astler Coller; T=Tumour; N=Node; 
M=Metastasis 
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Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the  muscularis 
propria into the subserosa 
T4 Tumour directly invades other organs or 
structures, and/or perforates visceral 
peritoneum 
Regional lymph nodes (N) 
Nx Regional nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N2 Metastasis in 4 or more regional lymph 
nodes 
Distant metastasis (M) 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Presence of distant metastasis 
 
 
 
 
Stage 0 Tis, N0, M0 
Stage I T1, N0, M0 
T2, N0, M0 
Stage II T3, N0, M0 
T4, N0, M0 
Stage III Any T, N1, M0 or Any T, N2, M0 
Stage IV Any T, Any N, M1 
 
Table 1.3 TNM stage system of the UICC and AJCC; TNM definition, 1997 
31 
 
1.4 Treatment options and outcome 
 
1.4.1 Surgery 
 
Surgery remains the definitive treatment for apparently localised CRC, offering the 
only chance of cure. However the success of the surgery is dependent on site, stage 
and type of tumour.   
 
 
1.4.1.1 Surgery for Rectal cancer 
 
Heald and colleagues described the concept of total mesorectal excision (TME) for 
the treatment of rectal cancer in 1982. They proposed that a good circumferential 
clearance of the tumour by en block clearance of the mesorectum with its blood 
supply and lymphatic drainage would minimise possible disease relapse (34). Their 
experience of TME over 2 decades (1978-1997) showed a 68% cancer-specific 
survival at 5 years and 66% at 10 years for all surgically treated patients with a local 
recurrence rate of 6% at 5 years and 8% at 10 years (35).  Since then, there is sound 
evidence from large cohort studies to suggest that the use of TME in the treatment of 
middle and lower third rectal cancers reduces the risk of local recurrence and 
improves survival (36;37). Currently TME is the therapeutic gold standard for middle 
and lower third rectal cancers. 
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Certain rectal cancers are technically amenable to local excision. Transanal resection 
using transanal endoscopic microsurgery (TEM) was first described by Buess in 1983 
(38). TEM combines an endoscopic view of the rectum under gas insufflation via 
stereoscopic telescope with conventional surgical preparation. This enables the 
operator to remove the tumour using full thickness excision under direct magnified 
vision with sufficient margins of surrounding normal healthy tissue. The advantage of 
TEM is that it allows less invasive surgery with much more precise removal of the 
tumour (39;40) compared with conventional transanal surgical techniques, where 
only tumours in the lower rectum can be reached and the operative view is somewhat 
limited, which may partly be responsible for high rates of local recurrence seen in the 
Mayo Clinic study and the Cancer and Leukaemia Group B CALGB Intergroup 
Phase 11 study (22%)  (41). There is evidence from a randomised controlled trial that 
TEM is associated with less morbidity than radical surgery (42). Willett et al. 
reported no difference in the outcome of pT1 and pT2 carcinomas, having favourable 
histologic features, resected transanally or transabdominally (43). The 5 year 
recurrence free rates were 87% and 91% respectively and so TEM may have a role in 
the management of selective early rectal cancers.  
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1.4.1.2 Role of Neo-adjuvant Chemoradiation (CRT) in Advanced 
Rectal cancers 
 
In the Dutch study comparing TME with or without preoperative short course (25 Gy 
in 5 fractions) radiotherapy (RT), preoperative RT significantly improved local 
control compared in operable tumours compared with TME alone without impacting 
on survival (44). Preoperative long course chemo-radiation is the current standard 
treatment for locally advanced rectal cancers where the MRI scan suggests that the 
circumferential resection margin (CRM) is involved or threatened.  In rectal cancer, 
involvement of the histologic CRM, which is defined as tumour ≤1 mm from the 
resection margin, has been shown to be an important prognostic factor, resulting in 
both high rates of local recurrence and poor survival (45-48) even after TME surgery 
(49). More recently, preoperative long-course fluorouracil (FU) based 
chemoradiotherapy (CRT) has been shown to significantly improve local control 
compared with either postoperative CRT or preoperative long-course RT (45 Gy in 
25 fractions) (50). Chau et al. from the Royal Marsden Hospital, UK described 77 
patients with advanced rectal cancer based on MRI criteria who received 12 weeks of 
neoadjuvant chemotherapy followed by CRT. TME was planned 6 weeks after CRT 
and patients received another 12 weeks of capecetabine postoperatively. The 
radiological tumour response rate to chemotherapy was 88% and increased to 97% 
after CRT.  R0 resection was achieved in 99% of patients. Complete pathologic 
response was observed in 16 patients (24%) and 48% had microscopic tumour foci 
found only (51).  However further follow up would be required to see whether 
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reduction of distant metastasis and thereby improvement of overall survival can be 
achieved by this approach.  
 
 
1.4.1.3 Surgery for Colon Cancer 
 
There is little controversy regarding the resection of colonic tumours. Depending on 
the site of the tumour the disease segment of the colon is resected with wide margins 
and the cut ends are anastomosed to restore bowel continuity (figure 1.1). The no-
touch isolation technique in which the vascular supply to a tumour is divided before 
the tumour is handled has been tested in randomised controlled trial and shown to 
confer no significant advantage (52). West et al. have suggested that the quality of 
surgery for colonic cancer is associated with patient survival and that good-quality 
colon-cancer surgery involves removal of the mesocolon in the mesocolic plane, 
thereby producing a combination of an intact peritoneal-lined mesentery and a 
smooth fascial-lined surface that contains the primary tumour along with its draining 
blood vessels and lymphatics. Mesocolic plane surgery removes substantially more 
tissue around the tumour outside of the muscularis propria with a greater distance to 
the resection margins. A mesocolic resection translated into a 15% survival advantage 
at 5 years compared with surgery in the muscularis propria plane (53). Poor-quality 
muscularis propria plane surgery, in which one or more large defects are seen in the 
mesocolon going down onto the muscle layer, might not remove the entire primary 
tumour and disrupts the lymphatic and vascular drainage, potentially resulting in poor 
outcome.  
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Invasive carcinoma is present in 2-9% of colorectal polyps removed by endoscopy. 
Some malignant polyps may be managed by polypectomy at colonoscopy alone. In 
1985, Haggitt et al. (54) suggested a classification system for levels of invasion of 
carcinoma for pedunculated adenomas: Level 0, carcinoma in situ; Level 1, invasion 
through muscularis mucosa into the submucosa in the head of the polyp; Level 2, 
invasion into polyp neck; Level 3, invasion into the stalk of the polyp; and Level 4, 
invasion into the sub mucosa in the bowel wall below the stalk but above the 
muscularis propria. Sessile polyps are classified as Level 4 if carcinoma extends 
beyond muscularis mucosa. The Japanese have further classified sessile T1 polyps by 
subdividing the submucosa into thirds: sm1, 2 and 3 (superficial, middle and deep 
thirds, respectively), sm1 being invasion to a depth of 200-300µm; sm2, intermediate 
between sm1 and sm3 and sm3, carcinoma invasion near the muscularis propria. The 
risk of lymph node metastases is very low for cancers limited to the mucosa and 
upper third of the submucosa (sm1) (55;56). With sm2 involvement, there is 
substantially higher risk of lymph node metastases of between 5% and 100% (57). 
Akasu and colleagues found that for massive submucosal invasion which they 
defined as sm2 or sm3, the incidence rises to around 25% (58). In the Kikuchi study, 
of 105 patients with sessile-type polyps, 32 were classed as sm1. None of this group 
showed lymph node metastasis or local recurrence after at least 5-year follow up.  
Cohort studies indicate that further surgery is required only for incomplete excision, 
lymphovascular invasion, poorly differentiated tumours and Haggitt Levels 3 and 4. 
(59;60). 
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Right Hemicolectomy                                            Left Hemicolectomy 
        
 
 
                                     
 
           
      
 
Extended Right Hemicolectomy                            Sigmoid colectomy     
 
Figure 1.1 Colonic resections based on site of cancer 
Taken from the Johns Hopkins Medical Institutions, Gastroenterology & Hepatology 
Resource centre website (http://hopkins-gi.nts.jhu.edu/) 
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1.4.2 Chemotherapy in Colorectal cancer 
 
i) In a Metastatic / Palliative setting  
 
For several decades, 5-FU was the only effective treatment for advanced and 
metastatic CRC (61-64). Whilst many efforts were made to improve outcomes of 
patients by modifying doses, schedules, and combining 5-FU with modulators such as 
leucovorin, median survivals beyond 12 months were rarely achieved. With the 
introduction of chemotherapeutic agents such as oxaliplatin and irinotecan in the last 
decade, the median overall survival of patients with advanced CRC has improved 
from 12 months to about 18-21 months (65-67). In recent years, Phase III trials have 
shown that anti-angiogenic drugs such as bevacizumab [monoclonal antibody 
targeting vascular endothelial growth factor (VEGF)] and cetuximab [monoclonal 
antibody targeting epidermal growth factor receptor (EGFR)] when combined with 
chemotherapy have shown to improve survival in patients with advanced CRC. 
Bevacizumab has been shown, in a randomized trial, in the first line setting, to 
significantly improve overall and progression-free survival, and response rates 
compared to chemotherapy alone. In patients with irinotecan refractory disease who 
were most heavily pretreated, cetuximab appears to reverse chemoresistance when 
given together with irinotecan, resulting in an in an overall response rate of 22.9% 
(68-69). Studies are now investigating their use in the adjuvant setting. Multicentre 
international study such as QUASAR 2 is comparing ‘standard’ chemotherapy using 
capecitabine, against capecitabine + bevacizumab in histologically proven Stage III 
and Stage II (any one or more of the following: Stage T4, presence of lymphatic 
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invasion, vascular invasion, peritoneal involvement, poor differentiation) CRC’s with 
the expectation that adding bevacizumab to capecitabine may have the potential for 
improved relapse free and overall survival compared to capecitabine alone. 
 
 
ii) In an Adjuvant setting 
 
Despite curative surgical resection in 80% of patients with CRC, nearly 40% of them 
develop disease recurrence as a result of occult micrometasases at the time of surgery 
(70). Adjuvant chemotherapy aims to eradicate these cancer cells. Moertel et al. in 
1990 showed that surgery alone in stages II and III cured 55% of patients whereas the 
addition of 6 month 5-FU plus levamisole improved 3.5-year survival up to 71%. 
Their randomised trial also demonstrated that 5-FU plus levamisole reduced the 
recurrence rates by 40% (p=0.0001) and death rates by 33% (p=0.0007) in patients 
who underwent curative resection of Stage III (Duke’s C) colon cancer (71;72). For 
these patients, 5-FU in combination with folinic acid has been shown to improve 
objective response rates when compared to 5-FU alone (10-23%), although the 
median survival was not affected (11.5 Vs. 11 months) (61).  Oral fluoropyrimidines 
such as UFT/LV or capecitabine (Xeloda®), which are more convenient have been 
compared in randomized trials to IV bolus 5-FU/LV regimen and showed similar 
efficacy, and even a 3.6% improvement in RFS for capecitabine (Xeloda®)  (73) in 
stage III colon cancer. The Multicenter International Study of Oxaliplatin/5-
Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (Mosaïc) trial 
compared the combination of oxaliplatin with infusional 5-FU/LV (known as 
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FOLFOX 4) with infusional 5-FU/LV in 2246 patients resected for colon cancer 
including both stages II (40%) and III (74). Overall, FOLFOX 4 provided an 
improved disease-free survival (DFS) of 6.6% at 4 years (76.4 versus 69.8%) over 
infusional 5-FU/LV (75). In addition to the Mosaïc trial, the NSABP C-07 trial 
combining oxaliplatin with bolus weekly 5-FU/LV (FLOX) also showed a 4.9% 
improvement of 3-year DFS.  
 
For stage II CRCs, in the Moertel et al. trial, the 3.5 years RFS was 77% in the 
surgery alone arm and 84% in the adjuvant chemotherapy arm, a non-statistically 
significant difference. The Quick and Simple and Reliable Study for Colorectal 
Cancer Treatment (QUASAR) 1 study results published in 2004 demonstrated an 
improved 5-year relapse free survival (RFS) with weekly 5-FU/folinic acid compared 
to surgery alone with a small but statistically significant benefit of 3.6% over surgery 
in stage II (node negative disease) (76;77). In the International Multicentre Pooled 
Analysis of B2 Colorectal Cancer (IMPACT B2) trial, the 5 year RFS was 73% with 
surgery alone and 76% with adjuvant 5-FU/LV (not statistically significant) (78). In 
the Mosaïc trial the benefit for stage II CRCs was 3.5% with FOLFOX, reaching 
5.2 % in high risk stage II as compared to 5-FU/LV.  Based on Moertel et al., 
QUASAR1 and IMPACT B2 studies, 73-77% of stage II patients are cured with 
surgery alone at 3.5-5 years. Therefore out of 100 stage II patients, potentially only 3-
7% will benefit from additional 5-FU/LV and only 3.5% will benefit from additional 
oxaliplatin over 5-FU/LV alone. The American Society of Clinical Oncology in their 
guidelines defines stage II patients with high risk disease who should be considered 
for adjuvant chemotherapy. These are patients with adverse prognostic factors such as 
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poorly differentiated or T4-stage histology, inadequate lymph node harvesting at 
surgery (less than 13 negative lymph nodes), extra mural venous invasion or 
presentation with perforation (79). 
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1.5 Mechanism of action of chemotherapeutic agents used in 
colorectal cancer 
 
5-Fluorouracil (5-FU): 5-FU is a fluorinated derivative of the pyrimidine uracil 
and is currently used as first line therapy for colorectal cancer.  It is a cell cycle phase 
specific anti-metabolite drug which, during S phase, exerts its anticancer effects via 
two main mechanisms: through mis-incorporation into RNA during synthesis, 
disrupting normal RNA processing and function, and by inhibition of thymidylate 
synthase, the enzyme responsible for providing the de novo thymidylate required for 
DNA replication and repair (80). Fluorouracil is usually administered with leucovorin, 
a reduced folate, which stabilizes the binding of fluorouracil to thymidylate synthase, 
thereby enhancing the inhibition of DNA synthesis. Although regimens involving 
continuous intravenous infusion were previously perceived as being more expensive 
and less convenient than bolus regimens, recent analyses suggest that differences in 
cost and quality of life between the bolus and prolonged-infusion schedules are 
marginal (64;81-82). Furthermore, continuous infusion appears to be moderately 
more effective than a rapid bolus approach (83). 
 
 
Ralitrexed (Tomudex): is a quinazoline folate analogue that selectively inhibits 
thymidilate synthase. The response rates of ralitrexed in advanced colorectal cancer 
(Phase III studies) have been similar compared to the Mayo regimen (bolus 5-FU). 
However the CRO6 trial indicated that ralitrexed was inferior to the de Gramont 
regimen (Infusional 5-FU) in terms of treatment related deaths, progression free 
42 
 
survival and quality of life (84). Despite this disappointing result, there is probably a 
group for whom ralitrexed will be preferable (e.g. cardiac contraindications to 5-FU 
based therapy), and this agent is currently being assessed with other cytotoxic agents. 
 
Oxaliplatin: Oxaliplatin is a third-generation platinum derivative that forms bulky 
DNA adducts and induces cellular apoptosis (85). Despite the ineffectiveness of other 
platinum-based drugs (such as cisplatin and carboplatin) in the treatment of colorectal 
cancer, preclinical data from human cell lines suggested that oxaliplatin held promise 
in treating this disease (86). Furthermore, oxaliplatin and fluorouracil were shown to 
be highly synergistic, not only in preclinical models but also in subsequent clinical 
trials (87;88). A potential mechanism for this synergy is the down-regulation of 
thymidylate synthase by oxaliplatin, which thereby potentiates the efficacy of 
flurouracil (89).  
 
Irinotecan: Irinotecan (also known as CPT-11) is a semisynthetic derivative of the 
natural alkaloid camptothecin, which exerts a cytotoxic effect through its interaction 
with the enzyme topoisomerase I (90). This enzyme is involved in the uncoiling of 
DNA for replication and transcription, and it causes single-stranded DNA breaks. 
Such breaks are normally transient and repaired; however, camptothecin stabilizes 
these breaks, leading to DNA fragmentation and cell death through interaction with 
the replication fork. 
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1.5.1 Targeted agents 
Bevacizumab 
VEGF is one of the most important regulators of angiogenesis during normal and 
pathological processes, and is expressed in approximately 50% of CRCs (91). VEGF 
mediates its action by binding to its receptors on the surface of endothelial cells, 
thereby stimulating endothelial cell proliferation.  VEGF has also been shown to be a 
potent survival factor protecting endothelial cells from apoptosis via activation of 
PKC or phosphatidylinositol 3'-kinase (PI3)-Akt pathways and upregulation of anti-
apoptotic proteins such as Bcl-2, XIAP and survivin (92-95). Bevacizumab binds to 
VEGF, neutralizes its biological properties and prevents interaction with its receptors 
(VEGFR). Its effect on cellular apoptosis is thus likely to be indirect as it targets a 
soluble ligand (VEGF) rather than its receptor.  
 
 
Cetuximab 
EGFR is overexpressed   in 77% of CRC and is involved in tumour growth and 
metastasis through interference in mechanisms of cell proliferation, apoptosis and 
neoangiogenesis (96). Cetuximab inhibits ligand-induced tyrosine kinase-dependent 
phosphorylation and downstream signalling of the EGFR, effecting an inhibition of 
cell proliferation in several different human tumour lines in vitro and in xenograft 
tumour models in vivo (97). The DiFi human colon cancer cell line expresses high 
levels of EGFR and TGF-α and is uniquely sensitive to EGFR blockade which has 
been shown to result in cell cycle arrest and  upregulation of the pro-apoptotic factor 
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Bax resulting in apoptosis (98-100). As discussed already, combination with 
irinotecan with that of cetuximab in metastatic CRC that was refractory to treatment 
with irinotecan showed the rate of response superior to cetuximab alone. Of interest, 
Chung et al. reported 16 patients with "EGFR-negative" chemotherapy-refractory 
tumours that responded to Cetuximab suggesting that the beneficial effects are not 
entirely dependent on EGFR expression (101). 
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1.6 Apoptosis, Chemoresistance and Colorectal cancer  
 
Many patients with metastatic disease who undergo chemotherapy, will progress 
during initial treatment due to resistance to current chemotherapeutic regimens. A 
number of mechanisms for development of chemoresistance have been proposed. 
Decreased drug delivery due to disorganized blood supply in tumours (102), tumour 
microenvironment (103), hypoxia in tumour cells (104), increased drug efflux due to  
P-glycoprotein (P-gp) (105)  and proteins involved in the regulation of apoptosis  
have all been implicated. 
 
 
1.6.1 Apoptosis 
                                 
Basic knowledge of normal apoptotic pathways is essential in order to understand 
the disruption of these pathways that takes place in colorectal and many other 
cancers thereby leading to cellular drug resistance. In 1972, Kerr et al. introduced 
the concept of apoptosis as a form of cell death that was distinct from necrosis 
(106). Apoptosis is a genetically controlled physiological cell death programme that 
occurs in all eukaryotic organisms and controls normal cell numbers during 
development and disease. Apoptosis is mediated by caspases (enzymes that belong 
to a family of cysteine proteases)  that cleave a series of cellular substrates to bring 
about  characteristic morphological and biochemical changes in the cell including 
chromatin condensation, nuclear fragmentation, membrane blebbing and cell 
shrinkage (107). The cell eventually breaks down into small membrane-bound 
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fragments (apoptotic bodies) that are cleared by phagocytosis without causing an 
inflammatory response. This physiological cell death programme is disabled in 
cancer cells resulting in their uncontrolled proliferation and growth. Apoptosis can 
be selectively induced in these cancer cells by using chemotherapeutic agents 
thereby checking this uninhibited cell growth.  
 
 
Non Apoptotic forms of cell death  
 
Despite the widespread occurrence of apoptosis in physiological and pathological cell 
death, other alternative morphological forms of cell death exist. These forms of cell 
death include 1) Necrosis, a form of passive cell death  which  is characterised 
morphologically by vacoulation of the cytoplasm, breakdown of the plasma 
membrane and inflammation around dying cell due to the release of cellular contents 
and pro-inflammatory molecules (108). Although considered to be an accidental 
uncontrolled cell death process until recently, growing evidence supports the idea that 
the necrotic cell death may also be programmed (109).  2) Autophagy, an intracellular 
lysosome-mediated catabolic mechanism that is responsible for the bulk degradation 
and recycling of damaged or dysfunctional cytoplasmic components and intracellular 
organelles (110). This can be stimulated in response to different situations of stress 
such as starvation, changes in cell volume, oxidative stress, hormonal signalling, 
irradiation, or xenobiotic treatment (111). Following induction of autophagy, 
autophagic vesicles are formed through the assembly and expansion of double-
layered, membrane-bound structures of endoplasmic reticulum around whole 
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organelles and isolated proteins. The autophagic vesicle encapsulates the cytosolic 
materials, then docks and fuses with the lysosomes or other vacuoles, causing 
degradation of the contents of the autophagic vesicle. 3) Mitotic catastrophe is a 
highly conserved stress response mechanism that causes cell death due to aberrant 
mitosis.  The cell can enter mitosis prematurely, before DNA replication is complete 
or DNA damage is repaired if the G2 checkpoint of the cell cycle is defective. This 
aberrant mitosis causes the cell to undergo death by mitotic catastrophe. It is 
associated with the formation of multinucleate, giant cells that contain uncondensed 
chromosomes, and is morphologically distinct from apoptosis, necrosis and 
autophagy (112). Defects in genes that are required for inducing mitotic catastrophe 
can contribute to carcinogenesis 4) Ischemia-related cell deaths featuring cell 
swelling referred to as oncosis (113) 5) Paraptosis is another form of programmed 
cell death that is distinct from apoptosis as it lacks the morphological hallmarks of 
apoptosis such as caspase activation, nuclear fragmentation, and is not inhibited by 
caspase inhibitors or the anti-apoptotic protein Bcl-XL.  Paraptosis is also associated 
with swelling of the endoplasmic reticulum and mitochondria, a feature that does 
not occur in cells undergoing apoptosis (114).  
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1.6.2 Apoptotic pathways 
 
The intrinsic and extrinsic are the two main interlinked pathways that can induce 
apoptosis by activation of caspases (figure 1.2). Based on their function, the 
caspases are classified into three subtypes. 1) Inflammatory caspases such as 
caspase-1, -4, -5, -11, -12, -13 and -14 that are involved in inflammation instead of 
apoptosis. 2) Apoptotic initiator caspases that possess long pro-domains containing 
either a death effector domain (caspase-8 and -10) or a caspases activation and 
recruitment domain (caspase-2 and -9) which mediates the interaction with 
upstream adaptor molecules. 3) Apoptotic effector caspases (caspase-3, -6 and -7) 
that are typically processed and activated by upstream caspases and perform the 
downstream execution steps of apoptosis by cleaving multiple cellular substrates 
(115). 
 
The intrinsic pathway is a mitochondrial mediated death process regulated by the 
Bcl-2 family of proteins which comprise of the pro-apoptotic proteins, Bcl-2 
homology 1-3 (BH 1-3) multi domain molecules such as Bax, Bak, Bad and Bcl-2 
homology 3 (BH3) domain-only molecules such as Bid, Bim, Puma and Noxa 
(which link the extrinsic pathway to the intrinsic pathway); and the anti-apoptotic 
proteins such as Bcl-2, Bcl-XL, and Mc1-1 (116) (Table 1.4).  DNA damage induced 
by radiation or chemicals, growth factor deprivation and oxidative stress initiates 
this pathway resulting in mitochondrial membrane permeabilization (MMP) and 
release of mitochondrial proteins including cytochrome-c, HtRA2/Omi and second 
mitochondria-derived activator of caspase/direct inhibitor of apoptosis protein 
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binding protein with low pI (Smac/DIABLO).  The MMP is facilitated by caspase-8 
which mediates the proteolytic maturation of pro-apoptotic Bcl-2 family protein 
Bid. Caspase-8 digested Bid, also called truncated Bid (t-Bid) translocates from the 
cytosol to the outer mitochondrial membrane attracted by the mitochondrion- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Apoptotic signalling in a cell 
Both the intrinsic and extrinsic pathways are closely inter-linked and most of the 
chemotherapeutic agents contribute to their cytotoxic function by activating either 
of these pathways.  
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Anti-apoptotic(Bcl-2) 
 
Pro-apoptotic (Bcl-2) 
Multi-domain ‘BH3 domain only’ 
 Bcl-2 
 Bcl-XL 
 Bcl-w 
 A1/Bfl-1 
 Mcl-1 
 NR-13 
 DIVA/BOO 
 
 
 
 
Bax 
Bak 
Bok 
Bcl-Xs 
Bcl-rambo 
 
 
 
 
 
 
Bid    
Bad                                                             
Bim/Bod                                                      
Bik/Nbk                                                      
Hrk                                                             
Blk     
Bmf         
Nix 
PUMA 
NOXA 
BNip3 
 
 
Table 1.4 The Bcl-2 protein family 
 
 
 
 
Protein Colorectal cancer Mechanism 
of chemoresistance 
   
p53 Mutation in 75% cancers Alters expression of apoptotic 
proteins such as Fas, Bax, NOXA, 
PUMA resulting in apoptotic 
dysfunction 
 
Bcl-2 & Bcl-XL Increased expression  Inactivates the intrinsic pathway 
 
Bax & Bak Decreased expression Inactivates the intrinsic pathway 
 
Survivin Increased expression Inhibits drug induced apoptosis 
 
 
Table 1.5 Apoptotic proteins and their mechanism of chemoresistance in 
colorectal cancer 
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-specific cardiolipin (117). Mouse studies have suggested that Bid-mediated MMP 
is dependent on the presence of either of two pro-apoptotic Bcl-2 proteins, namely 
Bax or Bak (118).  This t-Bid triggered Bax- dependent MMP results in full 
insertion of Bax in the mitochondrial membrane and its oligomerization to form a 
pore like structure, thereby promoting release of mitochondrial proteins (119). Once 
released from the mitochondria, cytochrome-c along with apoptosis protease 
activating factor-1 (Apaf-1) induces activation of caspase-9, resulting in initiation 
of the apoptotic caspase cascade.  
 
 Caspase activation is targeted by inhibitor of apoptotic proteins (IAPs) that bind to 
them and inhibit their proteolytic activity (120). Members of the IAPs - family of 
proteins include XIAP, c-IAP1, c-IAP2, NAIP, Survivin, Livin, Ts-IAP, and 
BRUCE (121;122). SMAC/DIABLO and HtrA2/Omi bind to and inactivate IAPs 
(123;124) thereby displacing them from their caspase binding (125).  
 
Anti-apoptotic proteins (Bcl-2 and Bcl-XL) sequester the pro-apoptotic BH-3 
domain only proteins in stable mitochondrial complexes, and thus prevent 
activation and translocation of Bax or Bak to mitochondria. In addition they also 
block apoptosis by preventing cytochrome-c release through a direct effect on the 
voltage-dependent anion channel (VDAC) found in the outer mitochondrial 
membrane (OMM). VDAC is the most common protein in the OMM and mediates 
high permeability to molecules of up to 5000 daltons in its open configuration 
(126). 
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The tumour suppressor gene p53 not only mediates G1 growth arrest by inducing 
the cyclin dependent kinase inhibitor p21/waf1/cip1 (127) but also regulates the 
intrinsic pathway in apoptosis by transactivating pro-apoptotic Bcl-2 family 
members and repressing anti-apoptotic Bcl-2 proteins and IAPs including survivin 
in response to DNA damage (128-130) (figure 1.2). Mutations in cancer cells 
commonly disrupt the intrinsic apoptotic pathway by either targeting p53 or Bcl-2-
related proteins. 
 
The extrinsic pathway is a receptor mediated and regulated by the members of the 
tumour necrosis factor (TNF) receptor superfamily namely; Fas (CD 95) and TNF 
related apoptosis induced ligand (TRAIL) receptors. Binding of these receptors with 
their ligands (FasL and TRAIL respectively), activates this pathway and results in 
oligomerization of the receptors and recruitment of the adaptor protein (Fas-
associated death domain (FADD) or TRAIL associated death domain (TRADD) 
respectively) and caspase-8, forming a death-inducing signalling complex (DISC). 
Autoactivation of caspase-8 at the DISC in turn cleaves and activates effector 
caspases (caspase-3, -6 and -7) (131). This pathway may be antagonised by cellular 
Fas-associated death domain-like interleukin-1beta-converting enzyme inhibitory 
protein (c-FLIP), by getting recruited to the DISC of death receptors, thereby 
disabling DISC-mediated processing and release of active caspase-8 (132).  
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1.6.3 Chemotherapy and Apoptosis in Colorectal Cancer 
 
Chemotherapeutic agents induce a series of cellular responses that impact on 
tumour cell proliferation and survival. Apoptosis is one such important cellular 
response and both in vitro and in vivo studies have effectively demonstrated that 
activation of the apoptotic pathways contributes to the cytotoxic action of most 
chemotherapeutic drugs (133;134) .  Both 5-FU and oxaliplatin, two of the main 
chemotherapeutic agents used in treatment of advanced CRC act by selective 
induction of apoptosis in colon cancer cells (135;136). Also combination treatment 
with 5-FU and irinotecan has been shown to induce apoptosis in various colon 
carcinoma cell lines (137;138). Studies have suggested that chemotherapy induced 
apoptosis involves activation of either the extrinsic pathway through Fas (CD95) 
receptor/ ligand system, or the cytochrome-c/Apaf-1/caspase-9 dependent pathway 
(intrinsic pathway) (139-143). Thus the ability of chemotherapeutic agents to 
trigger caspase activation appears to be a very important determinant of sensitivity 
or resistance to cytotoxic therapies (144;145). 
 
Individual proteins involved in apoptosis such as p53, Bcl-2, TRAIL and survivin 
can alter sensitivity of CRC to chemotherapy (Table 1.5). The present discussion 
focuses on how these apoptotic proteins can influence chemosensitivity and how 
modulating their action may enable us to develop therapeutic strategies that can 
help improve response rates to chemotherapy in patients with CRC.  
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1.6.3.1 p53 
 
Nearly 75% of CRC patients exhibit typical deletion of genetic material on 
chromosome 17 and 18 (146). The gene located on chromosome 17p encodes the 
p53 protein.  p53 can either halt cycle progression allowing DNA repair or induce 
apoptosis in the case of an irreparable insult of the genome (147). Loss in this fine 
balance due to mutations in p53 results in increased proliferation of colorectal and 
many other human cancers and also potentially increases their drug resistance due 
to decreased apoptosis.   
In vitro studies on four different colorectal cancer cell lines (HCT 116, RKO, 
RW2982 and SW403) showed that p53 played an important role in the apoptotic 
cascade initiated by oxaliplatin, and inactivation of p53 can lead to significantly 
increased resistance to oxaliplatin (136). Other in vitro studies on RKO colon 
carcinoma cell lines, MCF7 human breast cancer cell lines and in vivo studies on 
transgenic salivary tumour model in mice have shown that p53 inactivation does not 
lead to increase resistance to oxaliplatin (148;149) suggesting the role of p53 in the 
cellular response to oxaliplatin is complex and may depend on the tumour cell type 
or presence of other genetic alterations.  
The protein p53 can also transactivate apoptotic genes such as PTEN, Apaf-1, 
PERP (129;150-151) and others such as ferrodoxin reductase (FDXR) that lead to 
increase in reactive oxygen species. Reduction in the ROS production either by 
partial disruption of FDXR gene or addition of exogenous anti-oxidants can 
significantly reduce p53 mediated apoptosis following 5-FU treatment of colon 
carcinoma cells (152). The impact of p53 status on sensitivity of colonic cancers to 
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5-FU still remains controversial. In vitro  studies have shown that loss of p53 
function reduces chemosensitivity of CRC cells to 5-FU (153;154),  while others 
have shown that p53 overexpression in Stage III (155) and Stage IV (156) CRC 
patients correlated with resistance to 5-FU based chemotherapy.  This could 
possibly be explained due to tumour type differences in the effects of p53 
aberration.  
CRC often shows an impaired expression of the hMSH2, hMLH1, and hMLH3 
proteins (157-160). These proteins are involved in DNA mismatch repair, and a 
defect in their function will result in multiple genetic aberrations. These mismatch 
repair (MMR) proteins are also considered to regulate an apoptotic pathway in 
cooperation with p53 (161;162). Accordingly, DNA mis-match repair deficiency 
was found to be associated with resistance to cisplatin, carboplatin and 5-FU in 
colon cancer cell lines, which were additionally modulated by p53 activity (163-
165). 
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1.6.3.2 Bcl-2 family 
 
Bcl-2 family of proteins plays a pivotal role in the regulation of the intrinsic 
pathway.  Human colonic adenomas overexpress Bcl-2 compared to the surrounding 
normal mucosa (166;167). Once adenomas are transformed to invasive malignancy, 
although Bcl-2 expression tends to fall, expression of the anti-apoptotic protein Bcl-
XL becomes elevated (168;169).  
Mutations or altered expression of pro-apoptotic or anti-apoptotic Bcl-2 family 
proteins can drastically alter drug response in experimental systems (170). Reduced 
expression of Bax levels has been associated with poor responses to chemotherapy 
and shorter overall survival in CRC (171). In mismatch repair-deficient HCT116 
colorectal cancer cell lines, microsatellite instability at the Bax locus with 
consequent loss of Bax expression was identified as a mechanism of oxaliplatin 
resistance in vitro (172).  Arango et al. demonstrated that exposure of four different 
colorectal cancer cell lines (HCT 116, RKO, RW2982 and SW403) to oxaliplatin 
induced apoptosis by activation of the intrinsic pathway resulting in recruitment of 
Bax to the mitochondria, release of cytochrome-c and caspase-3 activation (136). 
Targeted inactivation of Bax in HCT 116 cells resulted in reduction in the number 
of cells displaying apoptosis following exposure to oxaliplatin.  Bcl-XL expression 
was identified as the strongest correlate of chemoresistance across 122 standard 
chemotherapeutics in an extensive study of genetic determinants of 
chemosensitivity in the NCI-60 cancer cell line panel (173).   
Violette et al. studied eight colon cancer cell lines and found that in p53+/+  cells , 
the basal level of Bcl-2  and Bax status correlated well to 5-FU resistance, however 
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in mutated p53 cells the Bax and Bcl-2 protein levels were not sufficient to predict 
5-FU resistance. They also showed that Bcl-XL replaced Bcl-2 and  was upregulated 
in all  p53+/+cells irrespective of the Bax status even during and  after 12 days of 5-
FU treatment, suggesting that this anti-apoptotic protein may play an important role 
in  maintaining  resistance to 5-FU  (174). In vitro studies using antisense Bcl-XL 
downregulation has been shown to increase sensitivity to 5-FU induced apoptosis in 
colorectal cell lines (175). Hayward et al. demonstrated enhanced oxaliplatin 
induced apoptosis in the mismatch repair-deficient HCT116 colorectal cell lines 
following antisense Bcl-XL downregulation. The extent of apoptosis enhancement 
depended on the integrity of the p53 and Bax mediated apoptotic pathway (176).  
 
 
1.6.3.3 TNF related apoptosis induced ligand (TRAIL) 
 
One of the important effects of TRAIL is the induction of apoptosis through binding 
its two pro-apoptotic receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5/Killer) 
leading to the formation of the death-inducing signalling complex (DISC). TRAIL-
R3 (DcR1) also called TRID and TRAIL-R4 (DcR2) also called TRUNDD, are the 
other two membrane bound receptors that cannot induce apoptosis (anti-apoptotic 
receptors), as they lack a functional cytoplasmic death domain. These two receptors 
are called decoy receptors as they protect cells from TRAIL-inducing apoptosis by 
competing with the death-inducing TRAIL receptors for TRAIL binding. 
Osteoprotegerin is the only soluble receptor that binds to TRAIL, but has low 
affinity at physiological temperature (177).   
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Immunohistochemical studies have demonstrated that these receptors are expressed 
in normal colon mucosa as well as colorectal adenomas and carcinomas and their 
expression is increased in malignant versus normal cells (178). Normal colonic 
epithelium is resistant to TRAIL induced apoptosis (179), whereas colon cancer 
cells are sensitive to recombinant human TRAIL in vitro and in vivo (180;181).  
Administration of TRAIL alone or in combination with chemotherapy in colon 
cancer xenograft studies have demonstrated its anti-tumour effect without showing 
toxicity against normal tissue (182;183). Naka et al. have further confirmed these 
findings by subcutaneously implanting fresh surgical specimens of colon cancer 
into SCID mice. Although heterogeneous in their growth rates in SCID mice, the 
tumour growth was significantly inhibited by TRAIL. They also showed that the 
anti-tumour activity of TRAIL could be greatly augmented by combination 
treatment with either 5-FU or camptothecin (CPT-11) and that combination of 
TRAIL with CPT-11 led to complete elimination of some of these tumours. Another 
interesting observation was that treatment with TRAIL alone or in combination with 
chemotherapeutic agents did not produce any observable toxic effects in the normal 
tissues examined (184).  
C-FLIP acts as an important negative regulator of TRAIL-induced apoptosis. Over 
expression of c-FLIP protects cells from TRAIL-induced apoptosis (185). Recent in 
vitro studies by Galligan et al. assessed the role of p53, TRAIL receptors and c-
FLIP in regulating the cytotoxic effects of recombinant TRAIL alone and in 
combination with chemotherapy (5-FU, oxaliplatin, and irinotecan) in a panel of 
colon cancer cell lines. They demonstrated that chemotherapy sensitized p53 wild-
type, mutant, and null cell lines to TRAIL-mediated apoptosis. They also showed 
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that although chemotherapy treatment did not modulate mRNA or cell surface 
expression of any of the TRAIL receptors (death receptor 4, death receptor 5, decoy 
receptor 1, or decoy receptor 2), it downregulated expression of the caspase-8 
inhibitor, c-FLIP (186). Thus in view of its clinical safety, TRAIL or agonistic 
TRAIL-receptor antibodies can be used to increase cell sensitivity to 
chemotherapeutic agents via induction of apoptosis in CRC. 
 
 
1.6.3.4 Survivin 
 
Survivin is the shortest member of the IAP family and has only one BIR domain. 
Survivin is upregulated by the T-cell factor/ β-catenin pathway following mutation 
of APC gene. Survivin is strongly expressed in embryonic and foetal organs but has 
not been reported in differentiated normal tissues with the exception of thymus, 
basal colonic epithelium (187) endothelial cells and neural stem cells during 
angiogenesis (188). Kawaski et al.  performed immunostaining on 171 CRC tissues 
and detected 91 specimens (53%) expressed survivin (189). The mechanism by 
which survivin inhibits apoptosis is not fully understood, although some studies 
have shown that it can either bind to caspase-3 and -7 (190) or inhibit caspase-9 
indirectly by binding to Hepatitis B X-protein which in turn binds caspases-9 (191). 
Tamm et al. have shown that survivin counteracts apoptotic stimuli induced by Fas, 
Bax, caspases, and anticancer drugs (192) although Asanuma et al. have shown that 
it can activate the extrinsic pathway of apoptosis by enhancing Fas ligand 
expression in colorectal cancer cells (193).  
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Survivin also regulates G2/M phase of the cell cycle by associating with 
microtubule formation in the mitotic spindle (194). This association is regulated by 
microtubule dynamics (195) and any disruption in the survivin-microtubule 
interactions results in loss of survivin’s anti-apoptotic function and activation of 
caspase-3 which results in apoptosis, during mitosis. This suggests survivin may 
counter-act a default induction of apoptosis in G2/M phase. The overexpression of 
survivin in cancer may overcome this apoptotic checkpoint and favour aberrant 
progression of transformed cells through mitosis. Tamm et al. investigated the 
expression of IAPs in the National Cancer Institute panel of 60 human cancer cell 
lines and showed that elevated survivin expression correlated with poor prognosis 
in colon cancer (196).  
Approaches to counteract survivin in cancer cells have been proposed in order to 
inhibit cancer growth through increase in spontaneous apoptosis and to enhance 
cancer cell response to apoptosis inducing agents (197). Previous in vitro studies 
showed that mutation of the cysteine residue at position 84 (Cys84Ala) of survivin 
generates a dominant-negative mutant that triggers mitotic catastrophe and 
apoptosis.  Based on these findings, Tu et al. transduced colon cancer cells with 
adeno-associated virus (AAV)-mediated survivin mutant (Cys84Ala) and 
investigated its therapeutic effect. They found that this survivin mutant induced 
apoptosis and mitotic catastrophe in colon cancer cells and inhibited angiogenesis 
and tumour growth in colon cancer xenograft model in vivo (198). 
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1.7 Fibroblast Growth factors 
 
Fibroblast growth factors (FGF’s) and their specific cell receptors (FGFR) make up a 
large and complex family of signalling molecules that have shown to play an 
important role in a variety of processes of embryonic development and tissue 
homeostasis and, when mutated or inappropriately expressed, can cause diverse 
pathologies ranging from morphogenetic disorders to cancer.  The FGF family of 
ligands include at least 22 distinct FGF’s numbered consecutively from 1 to 22 and 
have been identified in a variety of organisms including nematodes, drosophila, 
mouse and human (199). FGF’s and their signalling receptors have been associated 
with multiple biological activities, including cell proliferation, differentiation and 
motility. They have evoked interest as candidate oncogenes with a potential to initiate 
and/or promote tumourigenesis.  Several FGFs, including FGF-1 and FGF-2, stand 
out from typical growth factors in that they contain no consensus signal sequence for 
extracellular trafficking and secretion through the ER/Golgi (200). 
 
 
1.7.1 Fibroblast Growth factor-2 
 
Fibroblast growth factor-2 (FGF-2) is a member of this large family of structurally 
related glycoproteins that affect the growth, differentiation, migration and survival of 
a wide variety of cell types (201). FGF-2 was first identified in bovine pituitary 
extracts. The growth factor purified from these extracts resulted in increased 
mitogenic activity in the Balab/c3T3 fibroblast cell line (202). In addition to the 
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structural similarities between FGF-2 and other members of the FGF family, all of 
these growth factors bind to heparin and heparin sulfate. While heparin is only 
synthesized by connective tissue mast cells, heparin sulfates are widely distributed 
throughout mammalian tissues and organs attached to the core proteins as heparin 
sulphate proteoglycans (HSPGs). This heparin binding not only influences the 
biological activities of FGF-2 and other FGF’s, but also protects FGF-2 against heat 
or acid denaturation and protease cleavage (203). 
 
 
1.7.1.1 Structure of FGF-2 
 
FGF-2 occurs in several isoforms resulting from alternative initiations of translation: 
an 18 kD cytoplasmic isoform and four large molecular weight nuclear isoforms (22, 
22.5, 24 and 34 kD) (204). Sequence homology for FGF-2, across a wide range of 
species is very high (>90%). FGF-2 contains four cysteine residues with no 
intramolecular disulfide bonds, a large number of basic residues [isoelectric point 
(pI)=9.6] and two sites (Ser 64 and Thr 112) that can be phosphorylated by protein 
kinase A and C, respectively (201). While the binding of heparin and heparin 
sulphate has little effect on FGF-2 structure, it can facilitate the self-association of 
FGF-2 molecules into dimer and higher-order oligomers (203). In addition to the well 
documented interaction of FGF-2 with heparin sulphate chains, recent studies have 
indicated that FGF-2 and other FGF members might also interact with proteoglycan 
core proteins (205). The unique fgf2 gene has been mapped to band q26-q27 on 
human chromosome 4 and extends more than 36 kb; it is composed of three exons 
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seperated by two 16 kb introns, and possesses large 5’ and 3’ non- coding regions 
suggesting that there is regulation of its transcription (206). 
 
 
1.7.2 Fibroblast growth factor receptors 
 
The signalling of FGF-2 is by interaction with specific cell surface receptor proteins 
derived from four separate genes (FGFR1-4) that mediate binding and signal 
transduction for the entire family of FGF family of growth factors (207).The four 
receptors are structurally similar, each having 2-3 extracellular immunoglobin-like 
domains, a large intra-cellular juxtamembrane domain, and a split tyrosine-kinase 
domain (figure 1.3). Each FGFR gene can produce multiple mRNAs through 
alternative splicing that yield distinct receptor isotypes. The splice variants confer 
specificity in signalling in response to the various FGF family members. The 
inclusion or exclusion of alternative exons in the third Ig-like domain produces 
different ligand specificity in the different receptor isotypes. FGF-2 binds primarily to 
receptor isotypes containing the IIIc rather than the IIIb version of this exon and has 
high affinity for FGFR-1 and -R2, and to a lesser extent FGFR-3 whereas   FGF-1 
binds with roughly equal affinity to isotypes containing either version (208). 
FGF-2 has been proposed to have two separate receptor binding sites which might 
allow a single FGF-2 to bind to two receptors or to interact with a single receptor in 
two separate positions (209). HSPGs can increase the affinity of FGF-2 for its 
receptors (210) and potentially act as a bridge to facilitate the dimerization of the 
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receptors. A heparin binding site on FGFR-1 has also been identified, providing 
additional evidence that a ternary complex of FGF-2, HSPG and receptor exist.  
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 Figure 1.3: Structure of Fibroblast growth factor receptor 
(Numbers in parenthesis indicate the last amino acid of each domain in the FGFR-1 
protein) 
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1.7.3 FGF-2 signalling 
 
FGF-2 binding to the FGFRs activates multiple signal transduction pathways that are 
often inter-dependent. Upon ligand binding, receptor dimers are formed and their 
intrinsic tyrosine kinase is activated causing phosphorylation of multiple tyrosine 
residues on the receptors. These then serve as docking sites for the recruitment of 
SH2 (Src homology-2) or PTB (phospotyrosine binding) domains of adaptors, 
docking proteins or signalling enzymes. Signalling complexes are assembled and 
recruited to the active receptors resulting in a cascade of phosphorylation events 
(211). 
Genetic and biochemical experiments have helped to elucidate the signal transduction 
pathways concomitantly activated by FGFs in most cell types. The best understood of 
these are the Ras-MAP kinase pathway which include ERK1/2, p38 and JNK kinases; 
the P-I-3 kinase-AKT pathway, and the PLCγ pathway (212). The activation of 
ERK1/2 and p38 in response to FGF has been observed in all cell types, while the 
activities of other signal transduction pathways varies depending on the cell type.   
A key component of FGF signalling is the docking protein FRS2α which is 
phosphorylated on tyrosine residues upon FGF stimulation. It serves as an essential 
core upon which a signalling complex consisting of the tyrosine phosphatase Shp2, 
the adaptor Grb2, and the docking protein GAB1 is formed, leading to the activation 
of the Ras-MAP kinase and PI-3 kinase/AKT pathways (213). The FRS2 signalling 
complex recruits the guanine nucleotide exchange factor SOS, via binding through 
Grb2, which activates Ras and the downstream effectors of MAP kinase. Lamothe et 
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al. have shown that GAB1 is required for the stimulation of the AKT pathway by 
FGF (214). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: FGF-FGFR interaction mediated intracellular pathways 
 
 
The MAP kinases are a family of proteins that regulate the activity of downstream 
kinases or transcription factors. This family shares many structural similarities and 
includes the ERK1/2 kinases which are considered responsible for the mitogenic 
response, while the p38 and the JNK MAP kinases are usually associated with 
inflammatory or stress-responses (215). Although many p38 and JNK- activating 
stimuli are usually pre-apoptotic, the response to p38 and JNK activation appears to 
be cell-type specific. The ability of growth factors to protect from apoptosis is 
primarily due to activation of the AKT survival pathway. P-I-3 kinase dependent 
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activation of PKD leads to the activation of AKT which in turn affects the activity or 
expression of pro-apoptotic factors, which contribute to the protection from apoptosis 
(212). AKT activation also blocks the activity of GSK-3β which could lead to 
additional antiapoptotic signals (216).  
 
 
 
 
Figure 1.5: Intracellular signalling pathway of FGF-2 
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1.7.4 FGF-2 mediated Chemoresistance in solid tumours  
 
 
FGF-2 has been shown to impose not only mitogenic and pro-angiogenic effects on 
tumour cells but has been implicated as a potential regulator of tumour growth (217). 
To control cell survival, FGF-2 exerts both anti-apoptotic (218;219) and pro-
apoptotic (220) signals on embryonic and differentiated cells in vivo .  
 
Since most of the chemotherapeutic agents exert their effect on tumour cells by 
induction of apoptosis as discussed previously, it has been hypothesized that FGF-2 
might provide chemoresistance to these agents by blocking apoptosis. These 
cytoprotective effects of FGF-2 were first reported on 3T3 fibroblast cell line exposed 
to chemotherapy. In these studies, 3T3 fibroblasts were transfected or virally 
transduced with an FGF-2 cDNA. FGF-2 overexpression produced resistance to N-
(phosponacetyl)-L-aspartate (PALA), etoposide and 5-FU (221;222). Ectopic 
expression of an FGF-2 cDNA containing a secretory pathway signal sequence was 
reported to provide resistance to cisplatin induced apoptosis in 3T3 cells (223). More 
recently, the effects of 18kDa FGF-2 versus High Molecular Weight (HMW) FGF-2 
on resistance to PALA has been investigated in 3T3 fibroblasts (224). Transfection 
with cDNA encoding only 18kDa FGF-2 produces only partial resistance to the drug, 
whereas full resistance is seen after transfection with the wild-type cDNA (all 
isoforms) or cDNA encoding only HMW FGF-2. In this case, resistance seems to be 
mediated by intracellular activities of FGF-2, as treatment of the cells with exogenous 
FGF-2 has no affect on PALA sensitivity. Ectopic expression of FGF-2 has also been 
shown to affect sensitivity to chemotherapeutic agents in human tumour cell lines. 
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Miyake et al. in their study on human bladder cancer cells that do not produce any 
endogenous FGF-2 showed an increased three to four-fold resistance to cisplatin 
following stable transfection with an FGF-2 cDNA (225).  In addition, the resistance 
of tumours to chemotherapeutic agents in vivo has been correlated to the levels of 
FGF-2 in the tumour microenvironment (226).  
 
The FGF-2 mediated anti-apoptotic signalling has shown to prevent cell death 
induced by several chemotherapeutic agents including paclitaxel, doxorubicin and 5-
FU in human prostate cancer cells and rat tumours (226). FGF-2 has also been shown 
to induce expression of Bcl-2 proteins in chronic lymphocytic leukaemia cell line and 
this has shown to have a direct correlation with resistance to chemotherapeutic drug 
fludarabine (227). Pardo et al. demonstrated that FGF-2 mediates resistance to 
etoposide in small cell lung cancer cell line by upregulating both Bcl-2 and Bcl-Xl at 
a protein level but not at a gene level (228). They also observed that FGF-2 blocks 
the expression of Bad, a pro-apoptotic protein that is induced by etoposide.   
 
FGF-2 is also known to regulate the expression of other apoptotic regulatory proteins 
such as IAPs. Addition of FGF-2 to cultures of endothelial cells induces the 
expression of survivin (188), and upregulation of survivin in endothelial cells is 
associated with protection with apoptosis induced by multiple chemotherapeutic 
agents (229). Western blot analysis has revealed that two members of the IAP family, 
XIAP and cIAP-1 are overexpressed in most small cell lung cancer cell lines, 
suggesting the possibility that these proteins play a role in the aberrant protection of 
SCLC cells from apoptosis. Addition of FGF-2 in H510 SCLC cell line induced a 
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further increase in both XIAP and cIAP-1 expression in a time dependent fashion, up 
to four-fold at 4 hours following addition of FGF-2. This increase in XIAP and c-
IAP-1 protein levels was blocked using PD98059, an inhibitor of MEK/ERK pathway, 
suggesting that activation of MEK/ERK pathway is necessary for this FGF-2 induced 
effect. These results suggest a possible involvement of these IAPs in the pro-survival 
activity of FGF-2. 
 
 
71 
 
Thesis Aims 
 
The thesis is an investigation on effects of fibroblast growth factor-2 (FGF-2) in 
offering resistance to colorectal cancer cell lines exposed to chemotherapeutic agents. 
The investigation seeks to elucidate mechanisms that account for FGF-2 mediated 
chemoresistance in colorectal cell lines at protein and gene level. 
 
Hypotheses  
  
1) FGF-2 has a protective effect on colonic cancer cell lines treated with 5-
Fluorouracil (5-FU). 
 
2) FGF-2 mediates chemoresistance via upregulation of anti-apoptotic pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
Materials and Methods 
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2.1 Cells 
 
2.1.1 Cell Lines 
 
The colorectal cell lines SW620 and SW480 were obtained from the European 
Collection of Cell Cultures (ECACC, CAMR, Porton Down, Wiltshire, UK). 
 
SW480, are immortalised human colonic adenocarcinoma cells (206) harvested from 
a 50 year old Caucasian male with Duke’s B colonic adenocarcinoma.  
  
SW620, cells are a colonic adenocarcinoma cell line harvested from the lymph node 
metastasis of a 50 year old Caucasian male with colonic adenocarcinoma. The line 
was derived from a metastasis of the same tumour from which the SW480 line was 
derived. 
 
Both cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(Invitrogen, Paisley, UK) supplemented with 10% (v/v) foetal calf serum (FCS) 
(Invitrogen, Paisley, UK); SC-DMEM. 
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2.1.2 Routine cell culture and cell storage  
 
Cells were maintained in standard humidified conditions (5% CO2, 37°C; Hera Cell 
incubator 50049916/a, Heraeus, UK) and harvested when sub-confluent.  All 
experiments were performed with cells between passages 5-30.  Standardised 
appropriate media volumes were used dependent on the size of the culture flask.  
 
Cells, growing as monolayers in 75 cm2 tissue culture flasks were subcultured every 
3-4 days. Spent culture media was removed by aspiration and 5 ml of 0.25% (w/v) 
Trypsin-EDTA (Invitrogen) in Dulbeccos Phosphate Buffered Saline (D-PBS; 
Invitrogen) added to each flask.  Cultures were incubated at 37°C for 3-5 minutes, 
until the cells began to lift off the base of the flask. Further trypsinisation was 
inhibited by the addition of SC-DMEM; the cell suspension was transferred to a 15 
ml centrifuge tube and submitted to centrifugation at 652 x g for 6 minutes at room 
temperature. The resultant cell pellet was resuspended in SC-DMEM and 1 ml 
inoculated into a new tissue culture flask containing a further 9 ml of SC-DMEM. 
Frozen cell stocks were stored in liquid nitrogen in the vapour phase (-196°C). 
Samples were thawed at room temperature and transferred to a sterile centrifuge tube 
containing 10 ml of SC-DMEM.  The cells were harvested by centrifugation and the 
supernatant discarded. Cells were seeded and allowed to adhere in normal fashion. 
Cell stocks for storage (1 ml) were frozen as per individual supplier’s protocols in 
SC-DMEM supplemented with 10% (v/v) Dimethyl Sulfoxide (DMSO, Sigma 
Chemical Company Ltd, Poole, Dorset, UK). Cell samples were frozen at -70°C for 
24 hours before transfer to liquid nitrogen. 
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2.2 Characterisation of FGF-2 and FGF-receptor expression in cell 
lines 
 
2.2.1 Reverse-Transcriptase PCR detection of FGF-2 and receptors  
 
In order to characterise expression of fgf-2 and its receptors (fgfr1, fgfr2, fgfr3 and 
fgfr4) at a gene level, both SW480 and SW620 cells (200,000) were plated in 3 ml of 
SC-DMEM in a 60 mm Petri dish, allowed to adhere overnight and incubated in 
serum free DMEM (SF-DMEM) for 24 hours to synchronise the cells.  Cells were 
lysed in 350 µl of cell lysis/binding buffer [RNAqueous® Kit (Ambion, Huntingdon, 
Cambridgeshire)] and samples stored at -20°C prior to further purification. 
 
2.2.1.1 Isolation and purification of RNA 
 
RNA was harvested using in accordance with manufacturer’s instructions.  Briefly, 
each cell lines were disrupted in 350 µl of cell lysis/binding buffer, guanidinium 
thiocyanate solution. This solution effectively lyses cells and inactivates endogenous 
ribonucleases. The cell lysate was then diluted with 350 µl of 64% (v/v) ethanol and 
applied to an RNA-binding glass filter fibre assembled in a collection tube. This 
solution was submitted to centrifugation for 1 minute at 10,000 rpm. The liquid in the 
bottom of the collection tube was then discarded. Proteins, DNA and other 
contaminants were removed in three rapid washing steps. 700 µl of Wash solution 1 
was initially added to the assembly, centrifuged for 1 minute at 10,000 rpm. The 
liquid at the bottom of the collection tube was once again discarded. 500 µl Wash 
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solution 2/3 was then added to the assembly and the previously mentioned step was 
repeated. Finally the empty filter/collection tube was centrifuged for 1 minute at 
10,000 rpm in order to make the filter dry.    RNA bound to the filter was eluted in 60 
µl of elution buffer.  Contaminating DNA from the samples was removed following 
incubation with 1 µl of DNase and 7 µl of DNase reaction buffer (DNase Free; 
Ambion) at 37°C for 1 hour.  The DNase reaction was stopped by the addition of 7 µl 
of DNase stop solution and centrifuged at 11,600 x g for 1 minute.  RNA was 
transferred to a fresh tube and stored at -70°C.  The quality of the purified RNA was 
assessed by electrophoresis of a 5 µl aliquot on a 1.8% (w/v) agarose: Tris-Acetate 
EDTA (TAE) gel containing 0.5 mg/ml ethidium bromide.  Samples were mixed with 
an equal volume of gel loading buffer [50% (v/v) glycerol; 0.1% (w/v) orange G] 
prior to electrophoresis for 1 hour in a submerged horizontal gel electrophoresis tank 
at 100 V and RNA visualised under UV light (figure 2.1). 
 
                   --SW620---  ---SW480--- -MW-  
Figure 2.1 Visualisation of RNA following purification of SW620 and SW480 cell 
lines. 5 µl of RNA extracted from SW620 and SW480 cell lines and ran on 1.8% 
agarose with ethidium bromide gel. RNA visualised under UV light  
MW: Molecular weight. 
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2.2.1.2 Reverse-transcriptase polymerase chain reaction (RT-PCR) 
 
cDNA was prepared from the RNA using the ImProm-II™ Reverse Transcription Kit 
(Promega Hampshire UK Ltd) according to the manufacturer’s protocol.  Total RNA 
(1µl) was incubated with 1 µl of oligo dT15 primer and 3 µl of water for 5 minutes at 
70°C.  mRNA was then amplified using 4  µl of 5x reaction buffer, 2 µl of 25 mM 
MgCl2, 1 µl of mM dioxynucleoside triphosphates (dNTPs), and 1 µl of reverse 
transcriptase in a total volume of 20 µl.  Reactions were incubated at 25°C for 5 
minutes, 42°C for 1 hour, and 70°C for 15 minutes in the thermocycler (Techne, 
Stone, Staffordshire, UK). 
 
The presence of fgf receptors 1-4, and fgf2 transcripts were determined by PCR using 
gene specific primers together with a gapD control, Table 2.1 describes the primer 
sequences used and the expected amplicon size. cDNA (1 µl) was amplified with 12.5 
µl of PCR mastermix (Promega) and 8 ng/ml each of the forward and reverse primers 
in a final volume of 25 µl.  PCR was performed in the thermocycler with the 
following conditions; 5 minutes at 95°C, 40 cycles of 95°C for 1 minute, 55°C for 1 
minute and 72°C for 1 minute and a final extension of 72°C for 7 minutes.  
Amplicons were visualised under UV light after electrophoresis on a 1.8% (w/v) 
agarose-TAE gel containing 0.5 mg/ml ethidium bromide.  Controls comprising PCR 
reactions containing 1 µl of the original RNA samples (diluted 1 in 20) were included 
to confirm the absence of contaminating DNA, a negative control, containing 1 µl of 
dH20 instead of cDNA was also included.  
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FGFR1 Forward CATCAACCACACATACCA 
   Reverse 
 
AGTCCGATAGAGTTACCCG 
 
FGFR2 
 
Forward 
 
GCCCAACAATAGGACAGTGC 
   Reverse 
 
CCGCTTTTCCATCTTTTCTG 
 
FGFR3 
 
Forward 
 
ACTGTCTGGGTCAAGGATGG 
   Reverse 
 
GTTCTTCAGCCAGGAGATGG 
 
FGFR4 
 
Forward 
 
CACTGGTACAAGGAGGGC 
   Reverse 
 
GTTATAGCGGATGCTGCC 
 
FGF2 
 
Forward 
 
TCAAAAGTTCGGCATAG 
   Reverse 
 
TGGGGAAGAATATCCATC 
 
gapD 
 
Forward 
 
GAAGGTGAAGGTCGGAGTC 
   Reverse 
 
GAAGATGGTGATGGGATTTC 
 
Table 2.1 Gene specific primer sequence for FGFR1, FGFR2, FGFR3, FGFR4, 
FGF-2 and Gap-D 
These were used to carry out RT-PCR in SW620 and SW480 colonic cancer cell lines 
79 
 
2.2.2 Detection of FGF receptors by Western Blotting 
 
2.2.2.1 Sample preparation 
 
Cultures of SW480 and SW620 in 75 cm2 tissue culture flasks were harvested by cell 
scrapping in 1 ml of SC-DMEM.  Collected cells (5-6 X106/ml) were transferred to 
1.5 ml microfuge tubes, centrifuged at 11,600 X g for 2 minutes and the harvested 
cells lysed in 100 µl of ice-cold 1% (v/v) Triton-X100 solution in D-PBS containing 
1 x Complete Roche Protease Cocktail Inhibitor (Roche Diagnostics Ltd, Bulges Hill, 
Sussex, UK).  
 
 
2.2.2.2 Bicinchoninic Acid assay (Total Protein assay) 
 
Protein concentration of each of the samples was determined using the bicinchoninic 
acid assay (BCA) (Pierce Chester, UK) (figure 2.2). The principle of the BCA relies 
on the formation of a Cu2+-protein complex under alkaline conditions, followed by 
reduction of the Cu2+ to Cu1+. The amount of reduction is proportional to the protein 
present. It has been shown that cysteine, cystine, tryptophan, tyrosine, and the peptide 
bond are able to reduce Cu2+ to Cu1+. BCA forms a purple-blue complex with Cu1+ in 
alkaline environments, thus providing a basis to monitor the reduction of alkaline 
Cu2+ by proteins at absorbance maximum 562 nm.  
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Figure 2.2: Standard curve of net absorbance versus protein sample 
concentration 
X axis: BSA standard (micrograms/ml) 
Y axis: Net absorbance at 562 nm 
 
 
2.2.2.3 Sodium-dodecyl-sulphate Polyacrylamide Gel Electrophoresis 
 
Samples were diluted to 1 mg/ml protein in lysis solution and 20 µl mixed with 5 µl 
of SDS-PAGE sample buffer (LDS sample buffer, Invitrogen) and applied to a 10% 
SDS-PAGE gel.  SDS-PAGE gels were made with a 10 % resolving gel [3 ml of 40 
% (w/v) acrylamide / bisacrylamide (BioRad Laboratories Ltd. Hertfordshire, UK), 
2.5 ml of 1.5 M Tris-HCl pH 8.8, 100 µl of 10 % (w/v) Sodium-dodecyl-sulphate 
y = 0.0002x + 0.1247 
R 2 = 0.9993
0 
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(SDS) , 4 ml of H2O, 100 µl of 10 % (w/v) ammonium persulphate (APS), 10 µl of 
N,N,N,N-tetramethylethylenediamine (TEMED)] and a 5 % stacking gel [0.52 ml of 
30% (w/v) acrylamide/bis acrylamide solution, 1.5 ml of 0.5 M Tris-HCl (pH 6.8), 
3.2 ml of H2O, 50 µl of 10% (w/v) SDS, 50 µl of 10% (w/v) APS and 5 µl of 
TEMED] as described by Laemmli (1970).  Electrophoresis was carried out in mini 
protean II gel apparatus (BioRad) at a constant voltage of 120V for 1 hour using Tris-
glycine running buffer [25 mM Tris-HCl; 250 mM glycine; 0.1 % (w/v) SDS].  
Molecular mass was determined by comparison with prestained standards (Sigma) 
consisting of aprotinin (6.5 kDa), lysozyme (16.5 kDa), b-lactoglobulin A (25 kDa), 
triosephosphate isomerase (32.5 kDa), aldolase (47.5 kDa), Glutamic dehydrogenase 
(62 kDa), MBP-paromyosin (83 kDa) and MBP-b-galactosidase (175 kDa).   
 
 
 
2.2.2.4 Western blotting 
 
Proteins on the SDS-PAGE gel were transferred to a 0.45 µm pore nitrocellulose 
membrane (Hybond C; Amersham, GE Healthcare, Chalfont St Giles, 
Buckinghamshire, UK) electrophoretically in a Mini Transblot Cell (BioRad) in SDS 
deficient tris-glycine buffer, in accordance with the manufacturers’ instructions, at a 
constant voltage of 80V for 1 hour.  For immunostaining the nitrocellulose transfers 
were incubated for 1 hour in PBS containing 2% (w/v) non-fat milk to block non-
specific protein binding. Transfers were then incubated in the appropriate primary 
antibody [0.5 µg/ml in 2% (w/v) milk/PBS solution] for 1 hour, washed three times in 
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PBS with 0.1% Tween 20 before incubation with an anti-monoclonal-species Horse 
Raddish Peroxidase- conjugated secondary antibody [0.25 µg/ml in 2% (w/v) 
milk/PBS solution] for a further 1 hour. Blots were washed three times in PBS with 
0.1% Tween 20 and treated with 3 ml of enhanced chemiluminescent agent (ECL 
Amersham) for 5 minutes in accordance with manufacturers’ instructions. Protein 
bands were visualised following exposure to X-ray film (Amersham) for between 30 
seconds to 2 hours. 
 
Antibodies used in this study comprised FGFR1 (Monoclonal Anti-human FGFR1 
Antibody, R&D systems), FGFR2 (Rabbit polyclonal IgG, Santa Cruz 
biotechnology,® inc.), FGFR3 (Rabbit polyclonal IgG, Santa Cruz biotechnology,® 
inc.).  FGFR4 was not used in our study as FGF-2 does not interact with FGFR4 
receptor as has been shown in previous studies. 
Protein levels of FGF-2 were measured using ELISA technique not only in SW620 
and SW480 cell lines respectively, but also in the blood samples collected from 
patients who underwent colonoscopy and were found to have normal findings 
(control group), patients who underwent surgery for operable colorectal cancer and 
patients who were either diagnosed with metastatic colorectal disease at initial 
presentation or progressed to metastatic disease after previous treatment. SW620 as 
well as SW480 cells were plated and grown in monolayers in 75 cm2 tissue culture 
flasks, allowed to adhere overnight and incubated in SF-DMEM for 24 hours to 
synchronise the cells.   
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2.3 Determination of effect of FGF-2 and 5-FU on cell numbers 
 
2.3.1 Cell proliferation and survival assays 
 
Cells (100,000) were plated in a total volume of 1 ml in 12 well tissue culture plates 
and allowed to adhere overnight.  All growth assays were performed in FCS deficient 
media (SF-DMEM).  To optimise the concentrations of FGF-2 cells were treated with 
0.25, 2.5 and 25 ng/ml FGF-2 (R&D Systems) and incubated at 37°C for 96 hours.  
The number of cells following treatment was determined using trypan-blue exclusion 
technique.  Briefly, 250 µl of 0.25% (w/v) Trypsin-EDTA was added to triplicate 
wells of cells and incubated at 37°C for 4-5 minutes, until the cells began to lift off 
the base of each well.  An equal volume (250 µl) of 0.4% (w/v) trypan blue solution 
(Sigma) diluted 1:1 in SF-DMEM was then added to each well and the cells were 
agitated.  Cells were then transferred to a haemocytometer counting chamber and the 
number of cells in each square counted.  The number of cells per well was then 
calculated.  Cells stained blue by the trypan blue solution were not included in the 
cell count and trypan blue only enters non-viable cells.  Controls comprised cells 
harvested and counted at 0 hours following treatment and cells counted following 96 
hours incubation in SF-DMEM only. 
 
In order to determine the optimum concentration of chemotherapeutic agent to use in 
subsequent assays, cells were treated with 12.5, 25, 50 and 100 µM of 5-FU (Sigma,) 
for 96 hours and the number of cells determined as described above.  
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2.3.2 Cell survival assays  
 
The effect of FGF-2 in protecting cells against 5-FU activity was determined 
essentially as described above.  Cells (100,000) were pre-treated with 0.25 ng/ml 
FGF-2 or SF-DMEM for 4 hours prior to incubation with media containing 25 µM 5-
FU with or without the addition of 0.25 ng/ml FGF-2.  Cell viability was then 
measured over a period of 96 hours as described above. 
 
 
2.4 Measurement of apoptosis levels following FGF-2 and 5-FU 
treatment  
 
The Apo-One® Homogenous Caspase-3/7 assay (Promega) was used to determine 
the level of apoptosis in cells exposed to chemotherapeutic agent 5-FU pre-treated 
with or without 0.25 ng/ml FGF-2.  The Apo-One® Homogenous Caspase 3/7 assay 
consists of a non-fluorescent substrate rhodamine 110, bis-(N-CBZ-L-aspartyl-L-
glutamyl-L-valyl-L-aspartic acid amide) (Z-DEVD-R110) which is cleaved by the 
cellular caspases-3 and -7 activities to release free fluorescent rhodamine 110.  The 
amount of fluorescence product generated is directly proportional to the level of 
caspases-3/7 activity. 
 
Cells (10,000 in 100 µl) were cultured overnight in a 96 well assay plate with black 
walls and clear bottom (Costar®, Corning Incorporated, USA) before treatment for 4 
hours with SF-DMEM or 0.25 ng/ml FGF-2 in SF-DMEM as appropriate.  Cells were 
85 
 
then treated for 24, 48 and 72 hours with 25 µM 5-FU with or without 0.25 ng/ml 
FGF-2 as previously described.  Following incubation at 37°C for 24-72 hours, 100 
µl of reconstituted Apo-One® Homogenous Caspase-3/7 reagent was added to each 
well to be analysed and the fluorescence of each well was measured using a 
fluorometer (FLUOstar Optima, BMG LABTECH, Germany) at 10 minute intervals 
over a period of 5 hours with an excitation and emission wavelength of 499nm and 
521nm respectively.  
 
The level of fluorescence used to determine relative caspase activity between control 
(cells in SF-DMEM or 0.25 ng/ml FGF-2) and chemotherapy treated cells (with or 
without 0.25 ng/ml FGF-2) was taken at the mid-exponential phase of the assay.  The 
level of fluorescence per 1000 cells was calculated using cell numbers derived from a 
parallel cell survival assay performed essentially as described in section 2.3.2 but 
with 10,000 cells per well of a 96 well plate. 
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2.5 Analysis of pro- and anti-apoptotic protein expression during 
treatment 
 
2.5.1 RT-PCR analysis of bcl2, bclXl and bad gene expression 
 
Cells (200,000) were plated in 12 well plates, allowed to adhere overnight and 
incubated in SF-DMEM for 24 hours to synchronise the cells.  Cells were then treated 
in a) SF-DMEM (control), b) 0.25 ng/ml FGF-2,  c) 25 µM 5-FU or d) 0.25 ng/ml 
FGF-2 and 25 µM 5-FU and incubated at 37°C for 4, 8, 16 and 24 hours.  Cells for 
assays containing FGF-2 were pre-treated with 0.25 ng/ml of FGF-2 for 4 hours as 
previously described. 
 
Cells were lysed and RNA extracted from each sample and time point as described in 
section 2.2.1.1 and cDNA synthesised (section 2.2.1.2).  The presence of bcl2, bclXl 
and bad transcripts at each time point was determined by PCR using gene specific 
primers (Table 2.2) together with a gapD control (as previously described in section 
2.2.2.4).   Amplicons were visualised under UV light after electrophoresis on a 1.8% 
(w/v) agarose-TAE gel containing 0.5 mg/ml ethidium bromide.  Controls were as 
previously described.  
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2.6 Colorectal cancer tumour samples  
 
2.6.1 Sample Collection 
 
Colorectal tumour and normal colonic mucosa specimens were obtained from patients 
who underwent surgery for management of their colorectal cancer at St. Mary’s 
Hospital, London after having obtained appropriate consent. A Colorectal tumour 
tissue bank was established after obtaining the approval from the local research ethics 
committee. After surgical resection of the segment of the large bowel containing the 
tumour, the fresh specimen was taken from the operating theatre to the pathology 
department. Here the specimen was opened by the consultant pathologist (Dr. R 
Goldin, St. Mary’s Hospital London) and inspected. A 5mm3 section was removed 
from the main bulk of the tumour. Similarly another 5mm3 section was taken from 
the normal colonic mucosa atleast 5 cm away from the main tumour. The samples 
were immediately placed in liquid nitrogen. The samples were coded, anonymised 
and stored at -70°C until further analysis. Patient’s clinical details and final 
histopathological findings were recorded on a central database in accordance with the 
ethics approval and trust’s data protection and confidentiality policy. 
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2.7 Quantitative RT-PCR analysis of FGF and associated receptor 
expression in ex-vivo colorectal cancer tumour samples 
 
2.7.1 RNA purification from tumour samples 
 
To extract RNA, the frozen tumour samples were homogenised in a 6750 
Freezer/Mill®, (SPEX, CertiPrep, Stanmore, Middlesex, UK) to produce a fine 
powder.  Briefly samples were placed directly in a polycarbonate cylinder; containing 
a stainless steel impactor. The cylinder was placed in the liquid nitrogen filled 
chamber and subjected to 3 x 1 minute cycles of 60,000 impacts.  Homogenised 
sample was then transferred into a 15 ml centrifuge tube containing 3 ml of TRI 
Reagent™ (Sigma) to solubilise and stabilise the RNA. Samples were stored at -70°C 
prior to further processing.  
 
Samples were gently thawed and cellular debris was removed by centrifugation at 
652 x g for 6 minutes.  The supernatant (1 ml) was then transferred to a heavy phase 
lock tube (Eppendorf UK Ltd, Cambridge) containing 200 µl of chloroform.  The 
samples were mixed by inversion for 2 minutes and the samples centrifuged at 11,600 
x g for 10 minutes separating the mixture into three phases, the protein phase, DNA 
phase, and an upper aqueous phase containing the RNA. The upper aqueous phase 
was harvested and transferred to a new microfuge tube and 0.5 ml of isopropanol 
added to each tube.  Samples were left for 1 hour at -70°C for precipitation to occur, 
precipitated RNA was then harvested by centrifugation (11,600 x g, 10 minutes), the 
RNA pellet washed in 70% ethanol solution, centrifuged (11,600 x g, 2 minutes) and 
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the pellet air dried (10-15 minutes).  RNA was then re-suspended in 30 µl of Tris 
EDTA buffer and heated at 70°C for 5 minutes to facilitate solubilisation. The 
samples were then stored at -70°C until further analysis. RNA purity and integrity 
were determined by visualization on a 1% (w/v) agarose gel in 1 x TBE buffer 
containing 50 ng/ml ethidium bromide following electrophoresis (100 V, 45 minutes). 
Only RNA showing no degradation and a high 28S to 18S ratio was used. RNA 
solution was diluted 1 in 15 in DEPC water and quantified by absorbance at 260 nm 
(Ultrospec 2000, UV/Visible spectrophotometer, Pharmacia Biotech, UK). Total 
RNA concentration was determined by the following equation: [RNA] =A260 x 
Dilution factor x 40 µg/ml. The DNA/RNA were analysed as described in section 
2.2.1.1 and 2.2.1.2. 
 
 
2.7.2 q-PCR detection of  fgf2 and fgf- receptors 
 
cDNA was produced from the total extracted RNA using the ImPromII reverse 
transcriptase kit (Promega). Briefly 1µl of RNA was mixed with 1µl of olig dT 
primer and 3µl of dH2O and primers allowed to anneal at 72°C for 5 minutes 
followed by 5 minutes at 4°C. Following incubation 4 µl of 5x reaction buffer, 2 µl of 
25 mM MgCl, 1 µl of 10 mM dNTP mix and 1 µl of reverse transcriptase enzyme 
was added to each tube and mRNA amplified at 25°C for 5 minutes, 42°C for 1 hour 
and 70°C for 5 minutes. Quantitative PCR was performed on an Applied Biosystems 
7900 real-time PCR instrument using the Applied Biosystems Gene Expression 
Assay for fgf2 and fgfr’s; with the gene expression assay for gapDH used as a 
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reference. Each assay comprised 5 µL of master mix; 3 µL of nuclease free H2O, 1 
µL of 20X gene specific primer: probe (FAM) mix and 1 µL of cDNA and each assay 
performed in triplicate. Assays were performed under the following conditions, 50°C 
for 2 minutes, 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 
60°C for 1 minute. Levels of FAM fluorescence in each sample were measured 
during each cycle and plotted. The Ct values were determined automatically by the 
SDS software package (Applied Biosystems).  
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2.8 Enzyme Linked Immunosorbent Assay (ELISA)  
 
2.8.1 Bcl-2 and Bcl-XL anti-apoptotic protein estimation 
 
SW620 cells were plated and grown in monolayers in 75 cm2 tissue culture flasks, 
allowed to adhere overnight and incubated in SF-DMEM for 24 hours to synchronise 
the cells.  Cells were then treated in a) SF-DMEM (control), b) 0.25 ng/ml FGF-2, c) 
25 µM 5-FU, d)  0.25 ng/ml FGF-2 and 25 µM 5-FU and incubated at 37°C for 4, 10, 
24, 48 and 72 hours.  Cells for assays containing FGF-2 were pre-treated with 0.25 
ng/ml of FGF-2 for 4 hours as previously described. 
 
Cells were rinsed twice in PBS ensuring that all PBS was removed after the second 
rinse. Cells were then lysed in lysis buffer solution, vortexed briefly and allowed to 
sit on ice for 15 minutes. The individual samples were then stored at -70°C until 
further tests were carried out. Before estimation of specific proteins, the protein 
concentration in each sample was quantified using total protein assay (BCA) as 
previously described in section 2.2.2.2. Before use, samples were centrifuged at 2000 
X g for 5 minutes and the supernatant was transferred into clean eppendorfs. The 
samples were assayed by ELISA (DuoSet® IC, R&D Systems) according to the 
manufacturer’s protocol for Bcl-2 and Bcl-XL both sensitive to 60 pg/ml. This assay 
employed the quantitative sandwich enzyme immunoassay technique. 100 µl of capture 
antibody specific to Bcl-2 or Bcl-XL was precoated onto each well of a 96 well 
microplate. The microplate was sealed and incubated overnight at room temperature. 
Each well was aspirated and washed thrice with 400 µl of Wash Buffer per well for 
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each wash using a squirt bottle. Each well was then blocked with 300 µl of Block 
Buffer and incubated at room temperature for 1-2 hours. The wells were aspirated and 
washing of each well thrice was once again repeated. 100 µl of samples and standards 
were pipette into the wells and any Bcl-2/Bcl-XL present was bound by the 
immobilized capture antibody. After washing away any unbound antibody-enzyme 
reagent, a biotinylated detection antibody specific to either human total Bcl-2 or Bcl-
XL was used to detect the protein, using a standard Streptavidin-HRP format. 
Substrate solution was added to the wells and colour developed in proportion to the 
amount of either Bcl-2 or Bcl-XL bound in the initial step. The colour development 
was stopped and the intensity of the colour was measured by determining the optical 
density set to 450 nm in a 96 well reading spectrophotometer. 
 
 
2.8.2 FGF-2 protein estimation 
 
FGF-2 protein was estimated using ELISA (Human FGF Basic Immunoassay, R&D 
systems) and was carried out on i) SW620 and SW480 cell culture supernatants and 
ii) blood samples of patient’s with CRC who underwent surgical resection and CRC 
patients who developed metastatic disease. 
 
SW620 and SW480 colonic cancer cells were plated onto 75 cm2 culture flasks and 
allowed to adhere overnight in 10 ml of SC-DMEM. The SC-DMEM was then 
replaced with SF-DMEM) and incubated in for 24 hours to synchronise the cells. 
Following 24 hours of incubation, the supernatant from each culture flask was 
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aspirated and transferred into 15 ml centrifuge tubes. FGF-2 protein estimation was 
carried out on the supernatant samples. 
After having obtained appropriate consent, blood samples were collected from 
patients who were diagnosed with CRC prior to the surgical resection of their cancer. 
Blood samples were also collected from patients with known diagnosis of colorectal 
cancer who developed metastasis, before they started their treatment for metastatic 
disease. Samples were collected in serum separator tubes and were allowed to clot for 
30 minutes before centrifugation for 15 minutes at 1000 X g. Serum was aspirated 
from and transferred into clean epppendorfs that were stored at -70°C until further 
tests were carried out. 
This assay also employed the quantitative sandwich enzyme immunoassay technique. 
The samples were assayed by ELISA according to the manufacturer’s protocol for 
FGF-2 sensitive to 640 pg/ml. A monoclonal antibody specific for FGF basic was 
pre-coated onto a 96-well microplate. Standards and samples were pipetted into the 
wells and any FGF-2 present was bound by the immobilized antibody. The ELISA 
was performed essentially as described in section 2.8.1. After washing away any 
unbound substances, an enzyme-linked monoclonal antibody specific for FGF-2 was 
added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution was added to the wells and colour developed in 
proportion to the amount of FGF-2 bound in the initial step. The colour development 
was stopped and the intensity of the colour was measured in exactly the same manner 
as that for Bcl-2 and Bcl-XL protein estimation, described previously in section 
2.6.2.1. 
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2.9 Immunohistochemistry for colorectal cancer tumour samples 
2.9.1 Expression of fgfr1-4 in normal human colonic mucosal tissue 
and colonic cancer specimens by Immunohistochemistry 
 
FGFR1, FGFR3(C-15): sc-123, FGFR4 (c-16): sc-124, FGF-2 and Bek fibroblast 
growth factor receptor (FGFR2) antibodies (Santa Cruz Biotechnology Inc., CA 
USA) were optimized using an optimization tissue microarray assay (TMA) 
consisting of 12 cancers, 10 benign prostates and various normal human tissue. Each 
antibody was selected based on its use and validation in previous studies. Several 5 
mm-thick sections were cut from each paraffin embedded colorectal cancer tissue 
blocks. Sections were dewaxed in xylene and rehydrated through graded 
concentrations of alcohol. Antigen retrieval from paraffin embedded CRC tissue and 
colonic mucosa was achieved by immersion in 0.01 M sodium citrate buffer- pH 6.0, 
tris EDTA pH: 8 and microwaving for full 3 minutes (at 1000 W) in a pressure 
cooker. Primary antibodies for FGFR1-3 (1: 200) and FGFR4 (1:300) were added 
overnight at 4°C. Immunoreactivity was detected using biotinylated secondary 
antibody (Dako REAL ™ EnVision ™ Detection System, Peroxidase/DAB+, Rabbit/ 
Mouse). The reaction was visualised by Dako REAL ™ DAB+Chromogen. The 
slides were then counterstained with haematoxylin and viewed by two independent 
observers (RG, M.O, both Consultant pathologists). The degree of immunoreactivity 
in individual tissue section was described according to the tissue and cellular 
distribution and homogeneity and was scored semiquantitatively as percentage of 
stained carcinoma cells and intensity of staining in the section by two independent 
observers (RG & MO) as described in  shown in Table 2.2. Single immuno-reactivity 
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signals were scored for each case as being absent (0), weak (+), moderate (++) or 
strong (+++). Statistical analysis was performed by correlating FGFR expression with 
clinical parameters, using the Kruskal-Wallis test; p <0.05 was taken as being 
statistically significant. 
Scored for % 
stained 
  A  B C D 
0-10 11-25 26-50 51+ 
 
Scored for 
intensity 
0 1 2 3 
Negative Weak Moderate Strong 
 
Table 2.2 Scoring of Immunoreactivity expressed in percentage and degree of 
intensity of tissue staining 
 
 
 
 
Statistical Analysis 
 
All experiments were performed in triplicates and repeated three times. Mean +/- 
standard error of mean was calculated for each group tested in each experiment. P-
values were calculated using T-test for analysing difference between groups and a 
value of <0.05 was considered to be statistically significant.  Statistical analysis was 
performed for multiple comparisons between groups using the Kruskall- Wallis test 
and the Mann Whitney–U test was used to assess for differences between two groups. 
Statistics and graphs were prepared using SPSS 14.0 software package, Chicago, 
Illinois. 
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CHAPTER 3 
Characterisation of FGF-2 and Receptor 
expression in Colorectal Cancer Cell Lines 
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3.1 Introduction 
 
FGF-2 and its receptors have been observed in normal human colonic mucosa and in 
human colon carcinoma cells (230;231). FGF-2 is frequently upregulated in a variety 
of tumour types such as melanoma, glioma, hepatocellular and pancreatic carcinoma 
and has been shown to be mitogenic in colon cancer cell lines. FGF-2 is also often 
found at elevated levels in the blood and urine samples of cancer patients (232). In 
CRC, high circulating levels of FGF-2 is seen in patients with more advanced disease 
(233) and rising levels of FGF-2 has been shown to be associated with progressive 
disease (234). The latter study also demonstrated that disease progression during 
chemotherapy was more common in patients with high levels of FGF-2. Raised blood 
levels of FGF-2 is also known to have significant adverse prognostic impact in a 
variety of other tumours (235-238) and also predict treatment response in lung and 
breast cancer (239;240).  FGFRs are widely expressed in many tissues and different 
cell types, and the temporal control of their expression is an important mechanism for 
regulating physiologically relevant signals (207).  Studies have suggested that the 
inappropriate expression of FGFRs can contribute to malignant progression (241). 
Evidence from other studies also suggests that FGFRs are involved in several and 
sometimes opposing functions requiring tight regulation of their expression (242-244). 
 
We looked at expression of FGF-2 and its receptor expression in SW620 and SW480 
colonic adenocarcinoma cell lines both at an mRNA and protein level. 
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3.2 Results 
 
3.2.1 Constitutive gene expression of  fgf2 and receptors 
 
The gene expression of fgf2 and the receptors fgfR1, fgfR2, fgfR3 and fgfR4 in the 
colorectal cancer cell lines SW620 and SW480 was investigated by RT-PCR.   
The expression of fgf2 (approximately 250 bp), fgfR1 (350 bp), fgfR2 (200 bp),  fgfR3 
(350 bp) and fgfR4 (450 bp) was demonstrated in SW620 and SW480 cells (figure 
3.1). The expression of gapD (200 bp) in each cell line was used as a positive control.   
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    -------------------(a)-----------------     -----------------(b)------------------ 
 
Figure 3.1 Detection of fgf2 and receptor gene expression by RT-PCR 
The expression of fgfr1, r2, r3, r4, fgf2 and gapD in (a) SW620 and (b) SW480 (Lane 
1: fgfr1, Lane 2: fgfr2, Lane 3:fgfr3, Lane 4: fgfr4, Lane 5: fgf2 and Lane 6: gapD) 
Cells were grown in SC-DMEM and gene expression was determined by RT-PCR. 
Amplicons were visualised under UV light following electrophoresis on a 1.8% (w/v) 
agarose gel in TBE buffer containing 50 ng/ml ethidium bromide. 
      
       MW    1      2     3          MW     5     1     2      3      4     6  4     5    6 
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3.2.2 Analysis of FGF receptor proteins by Western Blot 
 
The presence of the FGF receptors FGFR-1, -2 and -3 in SW620 and SW480 cell 
lines were determined by western blot analysis.  Cell extracts were subjected to 
electrophoresis on a 10% SDS-PAGE gel (figure 3.2), transferred to a nitrocellulose 
membrane and probed with FGFR1,-2 and -3 specific antibodies.  SW620 and 
SW480 cells demonstrated the presence of FGFR1, -2 and -3 in the cell extract with a 
band at 75 kDa for FGFR1, 120 kDa for FGFR2 and 130 kDa for FGFR3, (figures 
3.3, 3.4 and 3.5).  
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Figure 3.2 SDS-PAGE gel of cell extract and supernatant 
The cell extracts from SW620 and SW480 cells were subjected to electrophoresis on 
a 10% SDS-PAGE gels and visualised by staining with Colloidal Coomassie Blue. 
Lane 1: Molecular weight marker, Lane 2: SW620 supernatant, Lane 3: SW620 cell 
extract, Lane 4: SW480 supernatant, Lane 5: SW480 cell extract. 
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             SW620              SW480                    SW1222               
Figure 3.3 Western blot demonstrating expression of FGFR-1 protein in SW620, 
SW480 and SW1222 cell lines 
 
 
 
 
 
        SW620                 SW480          SW1222  
Figure 3.4 Western blot demonstrating expression of FGFR-2 protein in SW620, 
SW480 and SW1222 cell lines 
 
 
75kDa 
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            SW620             SW480            SW1222 
 
Figure 3.5 Western blot demonstrating expression of FGFR-3 protein in SW620, 
SW480 and SW1222 cell lines 
 
 
 
         SW620                SW480                     SW1222 
 
Figure 3.6 Western blot demonstrating expression of tubulin (control) in SW620, 
SW480 and SW1222 cell lines 
 
130kDa 
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104 
 
3.2.3 Analysis of FGF-2 protein by ELISA 
 
The presence of FGF-2 protein in SW620, SW480 and SW1222 colonic cancer cell 
culture supernatants was determined using ELISA. 
The minimum detectable dose of FGF-2 was typically less than 3 pg/ml for the 
ELISA kit that was used for the assay. 
Our results demonstrated that FGF-2 protein expression was below the detection 
range in all three colonic cancer cell lines. 
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3.3 Discussion 
 
Our study demonstrated expression of fgf2 and fgfR1, 2, 3 and 4 at an mRNA level in 
SW620 and SW480 cell lines.    
 
Chandler et al. (245) determined the levels of fgf2 mRNA and each of the fgfr1-4 in 
sixty human tumour cell lines comprising the National Cancer Institute anti-cancer 
drug screen panel. This sixty human tumour cell line was derived from 9 cancer types 
and included 7 colonic adenocarcinoma cell lines, namely: KM-12, HCT-15, COLO-
205, SW620, HCT-116, HCC-2998 and HT-29. None of the colonic adenocarcinoma 
cell lines tested expressed fgf2. The expression of each of the fgf receptors was 
variable. Each receptor tested was detected in at least 3 out of the 7 cell lines. None 
of the cell lines had all receptors. Table 3.1 shows the variations in fgfr expression in 
these cell lines.  
 
The results of fgfR1-4 gene expression in SW620 cell line in our study were not 
consistent with the findings of Chandler et al. We demonstrated the mRNA 
expression of fgfr1, 2, 3 and 4 in SW620 cell line while Chandler’s study did not 
show expression of fgfr2.  Chandler et al. carried out assessment of FGF receptors 
and FGF-2 expression at an mRNA level only; however our study assessed both the 
mRNA as well as protein expression of the FGF receptors. Western blot analysis 
confirmed presence of FGFR-2 in SW620 cell line. 
Our study was also able to detect fgf2 gene in the SW620 cell line as opposed to 
findings of Chandler et al. who did not show any expression of fgf2.   
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Colonic 
adenocarcinoma 
cell lines 
fgfr1 fgfr2 fgfr3 fgfr4 fgf2 
KM-12 - + - + - 
HCT-15 + + + - - 
COLO-205 - - + + - 
SW620 + - + + - 
HCT-116 + + + + - 
HC-2998 - - - + - 
HT-29 - + - - - 
 
Table 3.1 fgf2 and fgfr1-4 mRNA expression in 7 colonic adenocarcinoma cell 
lines (245)  
 
Our results demonstrated expression of fgfr1 in SW480 cells.  This was once again 
not consistent with the findings of Jang who demonstrated overexpression of fgfr1 in 
a majority of human colon cancer cell lines except in SW480 cells (246). Moreover, it 
was shown that the disruption of fgfr1 expression by introducing fgfr1 siRNA was 
effective in elevating fgfr3 expression and inhibiting proliferation in these other cell 
lines. Thus, fgfr1 may confer a selectable advantage on clones of cells in colorectal 
tumourigenesis, favouring proliferation, whereas fgfr3 may have the effect of a 
tumour suppressor gene. Jang's study demonstrated that SW480 cell line express fgfr2, 
-3 and -4, but not fgfr1 and knockdown of fgfr3 by transfecting SW480 cells with 
fgfr3 siRNA resulted in expression of fgfr1 with decrease in expression of fgfr3.  This 
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reciprocal relation between fgfr1 and fgfr3 gene expression may play an important 
role in progression of CRC’s. Jang and his group in another study performed PCR-
single-strand conformational polymorphism analysis of the entire coding region of 
fgfr3 and the intronic sequences flanking each of its exons for mutation in genomic 
DNA on 40 primary CRC tissue samples obtained from patients who underwent 
surgical resection of their tumour to screen for DNA variants before direct sequence 
analysis. Sequences of abnormally migrating bands revealed three sporadic mutations 
in 2 of 40 colorectal tumour samples. The two somatic mutations occurred in a third 
Ig-like loop region (one in exon 7 and one in exon 9). The tumour DNA from CRC 
386C had a G to A transition at the first nucleotide of codon 322 which resulted in the 
substitution of Lys for Glu (247). To summarise, they showed that wild type FGFR3 
expression was reduced in human colon cancers, but two aberrantly spliced 
transcripts of FGFR3 were expressed suggesting these mutations impaired its tumour 
suppressor function. Therefore differences not only in receptor expression but also 
function may account for differences in response of colorectal cancer cells to 
chemotherapeutic agents. 
 
Our results of Western blot analysis for characterisation of FGFR expression 
demonstrated protein expression of FGFR1, -2 and -3 not only in SW620 but also in 
SW480 cell lines. Jang did not carry out protein expression of FGFR’s in their study, 
thus implying that their findings of no expression of fgfr1 in SW480 cells may not be 
real. 
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However, expression of FGF-2 was seen only at a gene level with low basal 
expression of FGF-2 at a protein level in both cell lines; the results of our ELISA for 
determining FGF-2 protein, however, demonstrated levels below the detection range 
for SW620, SW480 as well as SW1222 cell lines.  This suggests that FGF-2 
expression is predominantly an intra-cellular process and complex intracellular 
signalling mechanisms may be responsible for its extracellular secretion. In addition 
the translational products of FGF-2 mRNA may lack a signal peptide sequence that 
would ordinarily direct its secretion through the rough endoplasmic reticulum and the 
Golgi body. Galazie et al. performed immunoblotting for detection of FGF-2 on 
extracts of HCT 116A, HCT 116 B, 20-10-1, LS180, LS174T and ARK IA colonic 
carcinoma cell lines fractionated on heparin-Sepharose. FGF-2 immunoreactivity was 
found to be present in the 4 invasive colonic carcinoma cell lines HCT116B, 20-10-1, 
LS174T and ARK1A. No FGF-2 immunoreactivity was demonstrated in the non-
invasive HCT 116A or LS180 cells (248). This suggests that FGF-2 expression in 
CRC can be variable. 
 
Until now cell lysis and damage to the plasma membrane (due to apoptosis, chemical 
injury, irradiation, infection and chemotherapy) were the two mechanisms that were 
widely accepted for the secretion of FGF-2 in the peri-cellular space. Some recent 
studies have demonstrated other mechanisms of FGF-2 secretion from cells including 
ATP driven peptide pump mediated FGF-2 transport and involving a complex 
between FGF-2 and a carrier protein. Mignatti et al. witnessed the movement of 
single, isolated FGF-2 transfected NIH 3T3 cells stimulated by their own FGF-2, 
which was secreted into the extracellular space (249).  
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CHAPTER 4 
Effects of FGF-2 on Colorectal Cancer Cell 
Lines treated with 5-Fluorouracil 
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4.1 Does FGF-2 protect SW620 and SW480 colorectal cancer cells 
from the cytotoxic effect of 5-Fluorouracil? 
 
4.1.1 Introduction 
 
The development of tumour cell resistance to chemotherapy is the most frequent 
reason for failing to cure patients with common cancers (250). In addition to the 
mechanisms of chemoresistance discussed previously, studies have demonstrated that 
FGFs including FGF-2, can promote resistance to multiple chemotherapeutic agents 
both in vitro and in vivo (226). This is of interest because FGF-2 is frequently 
elevated in the serum of patients with various malignancies (234;251).  
Resistance to oxaliplatin and 5-FU, two of the most commonly used 
chemotherapeutic agents in CRC, has been demonstrated to be mediated via the anti-
apoptotic proteins Bcl-2 and Bcl-XL in CRC cell lines (174-176). There is significant 
evidence to suggest that FGF-2 alters the level of functional Bcl-2 and Bcl-XL 
proteins to modulate the threshold of chemotherapy induced apoptosis.  
 
Not much work has been done to investigate whether FGF-2 mediates 
chemoresistance in CRC’s. This chapter investigates whether FGF-2 protects SW620 
cancer cells from the cytotoxic effects of chemotherapeutic agent such as 5-FU.  
Because FGF-2 is involved in the regulation of Bcl-2 family of proteins, this chapter 
also investigates if FGF-2 reduces 5-FU induced cellular apoptosis in SW620 
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metastatic colonic adenocarcinoma cell line and if so does it actually alter the 
expression of pro- and anti-apoptotic proteins in this cell line exposed to 5-FU.  
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4.1.2 Results 
 
4.1.2.1 Effects of FGF-2 on proliferation in SW620 and SW480 cell 
lines 
 
The effects of addition of exogenous FGF-2 in varying concentrations to SW620 and 
SW480 cell lines were studied. 100,000 cells were treated with 0.25, 2.5 and 25 
ng/ml of FGF-2 respectively for 96 hours and then counted using trypan blue 
exclusion technique (section 2.3.1). Cell proliferation was compared to cells kept in 
control conditions. There was a significant increase in cell numbers in SW620 cell 
line with the addition of 2.5 ng/ml (245 X 103 +/- SEM, p=0.01) and 25 ng/ml (327 
X103 +/- SEM, p=0.03) of FGF-2 suggesting that these concentrations resulted in 
increased cellular proliferation. Similar results were seen in SW480 cell line (157 X 
103 +/- SEM, p=0.03 with the addition of 2.5 ng/ml and 159 X 103 +/- SEM, p=0.003 
with 25 ng/ml of FGF-2).  
 A concentration of 0.25 ng/ml of FGF-2 however did not result in cellular 
proliferation and the cell numbers (165 X 103 +/-SEM) remained almost equivalent to 
the SW620 cells (151 X 103 +/- SEM) (p=0.34) (figure 4.1a)  in SF DMEM media at 
the end of 96 hours. 
Similarly, 0.25 ng/ml of FGF-2 did not result in significant cellular proliferation in 
SW480 cells and the cell numbers (127 X 103 +/- SEM) remained almost equivalent 
to the  cells (115 X 103 +/- SEM) (p=0.095) (figure 4.1b) in SF DMEM media at the 
end of 96 hours. 
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A concentration of 0.25 ng/ml of FGF-2 was used to study various effects of 
chemotherapeutic agents on SW620 and SW480 cell lines in all subsequent studies so 
that the effect of FGF-2 on cell proliferation could be excluded.  
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Figure 4.1a 
 
 
Figure 4.1b 
 
Figure 4.1a and 4.1b Effect of varying concentrations of FGF-2 (ng/ml) on 
SW620 and SW480 cell lines at the end of 96 hours incubation (Combined results 
of three experiments) Control: cells incubated in SF-DMEM. 
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The efficacy of chemotherapeutic agent 5-FU was determined by incubating SW620 
and SW480 cells with different concentrations of 5-FU (0, 12.5, 25 and 50 µM) and 
the cell numbers were determined using trypan blue exclusion technique after 96 
hours treatment. A dose dependent response was observed when 5-FU was added to 
the cultured medium (SF-DMEM) containing SW620 (figure 4.2) as well as SW480 
cells (data not shown), the minimal concentration that could cause around 50% cell 
kill in both these cell lines was considered as optimal and this was 25 µM . 
 
 
 
 
Figure 4.2 Percentage cell survival in SW620 cell line after 96 hours incubation 
with 12.5, 25 and 50 µM of 5-FU 
Control: SW620 cells incubated in SF-DMEM. 
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4.1.2.2 FGF-2 offers cell protection to SW620 cancer cells treated 
with 5-Fluorouracil 
 
In order to determine whether FGF-2 protected against chemotherapy-induced 
apoptosis, SW620 cells were treated with 5-FU (25 µM) with or without pre-
treatment for 4 hours with FGF-2 (0.25 ng/ml) and viable cells were counted using 
the trypan blue exclusion assay following 96 hours incubation. A significant 
difference in cell survival between cells treated with FGF-2 and 5-FU compared to 5-
FU alone was noted (81% compared to 60%, p= 0.015) (figure 4.3a). 
Similar FGF-2 mediated cellular protection was not observed in SW480 cell line and 
the percentage of cells survival after 96 hours remained nearly the same (figure 4.3b). 
 
Figure 4.3a Percentage cell survival in SW620 cell line after 96 hour incubation 
with 25 µM 5-FU with or without 0.25 ng/ml of FGF-2   
The graph shows a significant difference in cell survival between cells treated with 
FGF-2 and 5-FU compared to 5-FU alone (81% compared to 60%, p= 0.015). 
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Figure 4.3b Percentage cell survival in SW480 cell line after 96 hour incubation 
with 25 µM 5-FU with or without 0.25 ng/ml of FGF-2  
The graph shows no significant difference in cell survival between cells treated with 
FGF-2 and 5-FU compared to 5-FU alone (59% compared to 55%, p= 0.35). 
 
 
 
 
 
 
 
 
 
 
118 
 
4.2 Effects of FGF-2 on Apoptosis in SW620 Colorectal Cancer Cell 
Line treated with Chemotherapy 
 
4.2.1 FGF-2 mediates improved survival in SW620 cancer cell line by 
attenuation of 5-FU induced cellular apoptosis 
 
In order to determine whether FGF-2 protected against chemotherapy-induced 
apoptosis and the cell protection was not due to FGF-2 mediated increased cellular 
proliferation, SW620 cells in SF- DMEM were treated with 25 µM concentration of 
5-FU with or without 0.25 ng/ml concentration of FGF-2 for 24, 48 and 72 hours 
respectively and caspase-3/7 activity measured using a fluorometric assay (described 
in section 2.4). 
It was observed that there was a significant reduction in the caspase-3/7 activity 
between cells treated with FGF-2 and 5-FU compare to 5-FU alone (p=0.04) (figure 
4.4a & b). This trend was also seen to continue at 48 and 72 hours (data not shown). 
 
As FGF-2 did not offer any protection to SW480 cells from the cytotoxic effects of 5-
FU, the caspase-3/7 activity was not assessed.  
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Figure 4.4a 
 
 
Figure 4.4b 
Figure 4.4a & 4.4b Apoptotic activity measured by Caspase-3/7 assay in SW620 
cells at the end of 24 and 48 hours 
These show a significant decrease in fluorescence activity in SW620 cells treated 
with 5-FU and FGF-2 compared to 5-FU alone (p=0.04 and 0.04 respectively). 
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4.2.2 FGF-2 does not upregulate anti-apoptotic bcl2 and bclxl gene 
expression in SW620 cancer cells exposed to 5-FU 
 
In order to investigate if FGF-2 mediates chemoresistance by upregulating anti-
apoptotic genes, SW620 cancer cells were pre-treated with or without 0.25 ng/ml of 
FGF-2 for 4 hours before addition of 25 µm 5-FU. The gene expression of bcl2 and 
bclxl were determined by RT-PCR using gene specific primers. Our results 
demonstrated no observed difference in the gene expression of bcl2 and bclxl in 
SW620 cancer cells pre-treated with or without FGF-2 and exposed to 5-FU (figure 
4.5). 
 
 
4.2.3 FGF-2 does not downregulate pro-apoptotic bad gene 
expression in SW620 cancer cells exposed to 5-FU 
 
RT-PCR studies using bad specific gene primers did not show any change in gene 
expression of bad in SW620 cancer cells pre-treated with or without FGF-2 and 
exposed to 5-FU (figure 4.5). 
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FGF-2        -                   +                        -                   + 
5-FU          -                    -                        +                   + 
 
Figure 4.5 Expression of  bcl2, bclXl  and bad  genes in SW620 colon cancer cells 
pre-treated with or without 0.25 ng/ml FGF-2 for 4 hours followed by exposure 
to 25 µM of 5-FU 
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4.2.4 FGF-2 does not upregulate anti-apoptotic Bcl-2 or Bcl-XL 
protein in SW620 cancer cell exposed to 5-FU 
 
Proteins from SW620 cancer cell line were harvested after 4, 10, 24, 48 and 72 hours 
treatment with FGF-2 and 5-FU or 5-FU alone respectively and subjected to ELISA 
with Bcl-2 specific antibody.  
There was no observed change in Bcl-2 protein expression in SW620 cancer cells 
exposed to 5-FU with FGF-2 at 72 hours (figure 4.6) compared to cells exposed to 5-
FU alone. Similar trend was seen at 4, 10, 24 and 48 hours.   
 
 
Figure 4.6 Expression of Bcl-2 protein in SW620 cells treated with FGF-2 plus 5-
FU compared to 5-FU alone by ELISA after 4, 10, 24, 48 and 72 hours treatment 
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Western Blot technique was carried out to detect the changes in protein expression of 
Bcl-XL in SW620 cells once again treated with same conditions as mentioned above. 
There was no observed difference in the expression of Bcl-XL proteins in SW620 
cells exposed to 5-FU with or without pre-treatment with FGF-2 (figure 4.7). 
 
Bcl-Xl                
β-actin        
FGF-2                 -                +              -              +               -                + 
5-FU                   -                 -              -               -               +                + 
 
Figure 4.7 Expression of Bcl-XL in SW620 cells treated with FGF-2 plus 5-FU 
compared to 5-FU alone by Western blot technique 
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4.3 Discussion 
 
Over the last several years, FGF-2 has emerged as a growth factor that is capable of 
modifying the sensitivity of normal and tumour cells to anti-cancer drugs. FGF-2 can 
produce both drug resistance and drug sensitization in different cell types treated with 
a variety of cytotoxic agents. The FGF-2 mediated anti-apoptotic signalling has 
shown to prevent cell death induced by several chemotherapeutic agents including 
paclitaxel, doxorubicin and 5-FU in human prostate cancer cells and rat tumours 
(226). 
 
Our studies on SW620 metastatic colonic adenocarcinoma cell line have clearly 
demonstrated that exogenous application of FGF-2 in concentrations that do not 
cause cellular proliferation offer significant protection to these cancer cells from the 
cytotoxic effects of 5- FU. It is also very interesting to note that this cytoprotection 
offered by exogenous application of FGF-2 is not seen in SW480 primary colonic 
adenocarcinoma cell line exposed to 5-FU.   
 
The results of our apoptotic (Caspase-3/7 fluorometric) assays have confirmed that 
FGF-2 protects SW620 colonic cancer cells from the cytotoxic effects of 5-FU by 
significant reduction in the process of chemotherapy induced apoptosis. Our results 
compared to similar study carried out by Pardo et al. investigating the effects of FGF-
2 on H510 small cell lung cancer (SCLC) cell line exposed to etoposide (228). Pardo 
et al. demonstrated that FGF-2 mediates resistance to etoposide in small cell lung 
cancer cell line by upregulating both Bcl-2 and Bcl-XL at a protein level but not at a 
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gene level. RT-PCR studies on SW620 colonic cancer cells exposed to 5-FU with or 
without FGF-2 did not show any significant change in expression of anti-apoptotic  
Bcl-2 and Bcl-XL both at  a protein as well as a gene level. Pardo et al. also observed 
that FGF-2 blocks the expression of Bad, a pro-apoptotic protein that is induced by 
etoposide.  Our studies demonstrated no change in expression of bad gene in SW620 
cancer cells exposed to 5-FU with or without FGF-2.   
ELISA and Western blot studies  also demonstrated that addition of FGF-2 did not 
result in change in either the expression of Bcl-2  or Bcl-XL proteins respectively at 
the end of 4 and 10 hours exposure of SW620 cancer cells to 5-FU. This trend 
continued at 24 and 48 hours. 
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CHAPTER 5 
Characterisation of FGF-2 and receptor 
expression in Colorectal Cancer tumour 
samples 
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5.1 Introduction 
 
 
FGFR overexpression has been observed in many different human cancers. FGFR1 is 
overexpressed and amplified in breast carcinoma (252). FGFR4 immunoreactivity is 
substantially higher in prostate cancer specimens than in benign prostatic hypertrophy 
specimens, and this elevated level of expression is associated with decreased survival 
(253). 
 
 In Chapter 3, we characterised the in vitro expression of FGF-2 and its receptors in 
SW620 and SW480 cell lines at gene as well as protein level. In this chapter, we 
investigate the expression and cellular localization of FGF-2 and its receptors in 
paired samples of CRC tissue and normal colonic mucosa obtained from patients who 
underwent surgical treatment for their CRC. Histopathology reports and information 
on pTNM staging for each CRC tissue analysed was recorded.  
 
The purpose of the study was to determine i)if any correlation existed between FGF-2 
or receptor expression and TNM stage and ii) if expression of FGFR’s changed 
between normal and CRC tissue. Immunohistochemistry studies were carried out on 
these paired samples in the Department of Histopathology, St. Mary’s Hospital, 
London with Dr. M Osborne and Dr. R Golding to detect their expression of FGF-2 
and FGFR protein’s as described in section 2.9. Quantitative real time RT-PCR 
studies were also carried out on the CRC tumour specimens along with their 
corresponding normal colonic mucosa by Dr. G Roberts to characterise the mRNA 
expression of FGF-2 and its receptors. Finally FGF-2 protein expression in culture 
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supernatants of SW620 and SW480 cell lines, and serum estimation of FGF-2  from 
blood samples collected from patients who underwent surgical resection of their CRC 
and those who developed metastatic disease. 
 
5.2 Results 
 
5.2.1 Expression of FGF-2, FGFR1, -2 and -3 in colorectal cancer 
tissue and their paired normal colonic mucosa by 
Immunohistochemistry 
 
10 paraffin embedded surgically resected colorectal tumours were obtained from the 
archival material in the Histopathology Department of St. Mary’s Hospital, London.  
In addition grossly normal mucosa atleast 5 cm away from the edge of the tumour 
was used concurrently as the paired normal tissue. Out of the 10 patients, 3 were 
males and 7 were females with age ranging from 59 to 83 years with a mean age of 
74.8 years. The site of the primary tumour, pathological TNM staging of the resected 
tumour specimens and their grading according to the World Health Organization 
(WHO) is shown in Table 3.2.  
 
Immunoreactivity studies demonstrated equal expression of FGF-2, FGFR-2 and -3 in 
all ten CRC’s and their corresponding normal colonic mucosa samples. FGF-2 
immmunoreactivity was predominantly nuclear in both these tissues.  
 
129 
 
There was no difference in expression of FGF-2, FGFR-2 and -3 between normal and 
CRC tumour samples. The expression also did not demonstrate any correlation with 
the degree of differentiation of tumours. 
 
 
pTNM  Number 
of 
patients 
Stage Grade Site 
pT2N0Mx 1 Stage I Moderately  
differentiated 
adenocarcinoma 
Rectum 
pT2N1MX 1 Stage 
III 
Moderately  
differentiated 
adenocarcinoma 
Sigmoid 
pT3N0Mx 1 Stage II Moderately  
differentiated 
adenocarcinoma 
Descending 
colon 
pT3N1Mx 3 Stage 
III 
Moderately  
differentiated 
adenocarcinoma 
2: Sigmoid 
 
1: Rectum 
pT4N0Mx 2 Stage II 1:Mucinous adenocarcinoma 
 
1:Moderately differentiated 
adenocarcinoma 
1: Caecum 
1: Sigmoid 
pT4N1Mx 2 Stage 
III 
1:Mucinous adenocarcinoma 
 
1:Moderately differentiated 
adenocarcinoma 
1:Transverse 
colon 
 
1: Rectum 
 
Table 3.2 Pathological staging, site and grade of colorectal cancer in patients 
who underwent primary surgical resection of their tumours 
Immunohistochemistry studies looking at the expression of FGF-2, FGFR1, -2 and -3 
were carried out on the tumour samples and their corresponding normal paired 
colonic mucosa. 
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FGFR-1 immunoreactivity was seen in all ten CRC tumour specimens and their 
paired normal colonic mucosa.  
One very interesting observation was that 60 % (6 out of the 10) CRC’s demonstrated 
increased intensity and percentage of staining when compared to their paired normal 
colonic mucosa (figure 5.1 a-d).  Out of the 6 CRC tumour samples, 4 demonstrated 
strong staining (> 50 %) and 2 demonstrated moderate staining (26-50%).  Of the 
remaining 4 tumour samples, 3 demonstrated negative (0-10%) whilst 1 exhibited 
weak (11-25%) staining. Of the paired 10 normal colonic samples, 9 demonstrated 
negative (0-10%) whilst 1 exhibited weak (11-25%) of staining. The increased 
expression of FGFR-1 in CRC tumour samples when compared to the paired normal 
colonic mucosa reached statistical significance (p=0.0002). 
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Figure 5.1a Immunohistochemistry study demonstrating FGFR1 expression in 
colorectal cancer and their corresponding paired normal colonic mucosa 
Total number of colorectal cancers (in green) and their corresponding normal colonic 
mucosa (in blue) on X axis and their scoring intensity for FGFR1 staining on Y axis. 
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Figure 5.1b Immunostaining demonstrating FGFR1 expression in skin (positive 
control) 
 
Figure 5.1c Immunostaining demonstrating FGFR1 expression in normal 
colonic mucosa 
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Figure 5.1d Immunostaining demonstrating FGFR-1 expression in colorectal 
cancer 
 
 
5.2.2 Estimation of fgf2 , fgfr1, -2, -3 and -4 genes in colorectal cancer 
tissue and their paired normal colonic mucosa by Quantitative-PCR 
 
fgf2 was expressed in 2 of the 10 CRC tissues examined. Only one of the ten normal 
paired colonic mucosa expressed fgf2. 
fgfr’s were expressed in 4 CRC tissues and 3 normal colonic mucosa specimens. The 
details have been described in Table 3.3. No differences were observed between 
carcinoma and matched normal mucosa 
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No. TNM stage Type of tissue fgf2 fgfr1 fgfr2 fgfr3 fgfr4 
1 T3N1MX Tumour _ _ + + + 
Normal _ _ _ _ _ 
2 T3N1MX Tumour _ _ _ _ _ 
Normal _ _ _ _ _ 
3 T4N1Mx Tumour _ + _ _ + 
Normal _ _ _ _ _ 
4 T4N0Mx Tumour + + + + + 
Normal _ _ _ _ _ 
5 T4N0Mx Tumour + + + + + 
Normal + + + + + 
6 T3N0Mx Tumour _ _ _ _ _ 
Normal _ + + _ _ 
7 T2N0Mx Tumour _ _ _ _ _ 
Normal _ _ _ _ _ 
8 T3N1Mx Tumour _ _ _ _ _ 
Normal _ _ _ _ _ 
9 T4N0Mx Tumour _ _ _ _ _ 
Normal _ _ _ _ _ 
10 T3N0Mx Tumour _ _ _ _ _ 
Normal _ _  + + + 
 
Table 3.3 Expression of fgf2 and fgfr genes by qRT-PCR in colorectal tumour 
samples of varying TNM stage and their paired normal colonic mucosa samples. 
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5.2.3 Estimation of serum FGF-2 levels in colorectal cancer patients 
by ELISA 
 
 Serum FGF-2 estimation was carried out in 9 patients’ who underwent primary 
surgical resection for their colonic cancer. Of  the 9 patient’s, 6 were males and 3 
were females with age ranging from 28 to 90 years and  a mean age of 69.7 years.  
FGF-2 was detected in the serum samples of only 2 of the 9 patients. One of the 
patients had 2 synchronous cancers in the transverse colon (pT3/T1N0M0) and had 
serum FGF-2 level of 1.8 pg/ml. The second patient had a serum FGF-2 level of 3.2 
pg/ml and had a recurrent rectal cancer (pT4N0Mx). He had undergone anterior 
resection 2 years ago, but had now developed local recurrence at the anastomosis site 
extending posteriorly in to the pre-sacral space. The pathological staging, site of 
primary tumour, the presence of lymphatic, vascular and peri-neural invasion are 
shown in Table 3.4. Serum FGF-2 estimation was also carried out in 4 patients who 
had undergone surgery for their CRC in the past but had recently developed liver 
metastases. There were 2 males and 2 female patients with age ranging from 69 to 88 
years with a mean of 72.3 years.  The time to develop liver metastases from the time 
of their surgery ranged from 12 months to 26 months with a mean of 16 months. 
FGF-2 was detected in the serum of all these patients and the expression levels were 
1.3, 2.3, 0.5 and 0.5 pg/ml respectively.  
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pTNM Staging Grade Site of 
tumour 
Vascular  
Invasion 
Lymphatic 
Invasion 
Peri-
neural 
invasion 
T4N1Mx III Moderately 
differentiated 
adenocarcinoma 
Sigmoid Yes No No 
T3/T1 
N0Mx 
I &II Moderately 
differentiated 
adenocarcinoma 
Hepatic 
flexure 
No No No 
 
T4N0Mx II Moderately 
differentiated 
intestinal 
adenocarcinoma 
Rectum 
(Recurrent) 
No No No 
 
T3N0Mx II Moderately 
differentiated 
adenocarcinoma 
Rectum Yes No No 
T4N1Mx III Moderately 
differentiated 
adenocarcinoma 
Sigmoid Yes 
widespread, 
extramural 
No No 
T3N1Mx III Invasive 
mucinous 
adenocarcinoma 
Transverse 
colon 
Yes 
widespread 
Yes 
widespread 
No 
T3N0Mx II Moderately  
differentiated  
adenocarcinoma 
Rectosigmoid Yes Yes No 
T3N0Mx II Moderately  
differentiated 
adenocarcinoma 
Rectum No No No 
T4N2Mx III Moderately 
differentiated 
adenocarcinoma 
Sigmoid Yes Yes No 
 
Table 3.4 Pathological staging, grade, site of primary tumour and the presence 
of lymphatic, vascular and peri-neural invasion in colorectal cancer patients 
who underwent serum FGF-2 estimation prior to surgical management 
 
 
5.3 Discussion 
 
There have been not more than two studies that have investigated the expression 
pattern of FGF-2   and only one study that looked into FGFR expression pattern at 
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both the RNA and protein level on paired samples of colorectal tumour and normal 
mucosa.  
 
Sundlisaeter et al. demonstrated downregulation of FGF-2 in colorectal tumour tissue 
compared with normal mucosa both at an mRNA level and protein level (254). 
Immunohistochemical staining for FGF-2 in tumour and normal epithelium was 
found to be negative whilst stromal cells demonstrated strongly positive stain. That 
FGF-2 is more scant in tumour than in normal tissues may be due to the relative 
abundance of epithelial cells in tumour tissue compared with a higher proportion of 
stromal cells in normal tissues. 
 
Lemoine et al. examined the expression of FGF-2 in 24 colorectal adenomas and 17 
colorectal adenocarcinomas using immunohistochemistry (255). FGF-2 distribution 
was restricted to the nuclei of epithelial cells and was seen in 71% of the adenomas 
and 76% of the adenocarcinomas. Compared with their corresponding normal colonic 
mucosa, FGF-2 expression was downregulated in 66% of colorectal adenomas and 
47% of colorectal adenocarcinomas. Our study demonstrated equal expression of 
FGF-2 both in normal and CRC samples irrespective of the T and N stage of the 
tumour. 
 
Sato et al. measured the relative expression levels of fgf1, fgf2, fgfr1 and fgfr2 mRNA 
in colorectal tumour samples and adjacent normal colonic mucosa obtained from 202 
patients who were recently diagnosed with CRC.  The found that the relative 
expression level of the fgfr2 gene was higher in normal adjacent mucosa than in 
138 
 
cancer, whereas the relative expression levels of the fgf1, fgf2 and fgfr1 genes were 
similar. Another interesting result of their study was that fgfr1 gene expression levels 
were unrelated to lymph node metastases and found to be higher in the presence than 
in the absence of liver metastasis (256). Our quantitative RT-PCR studies were 
carried out on colorectal tumour specimens and adjacent mucosa of patients with no 
known metastatic disease and this demonstrated variable expression of fgf2, fgfr1, 
fgr2 and fgfr4 genes. However the results of our immunohistochemical study 
demonstrated increased expression of FGFR-1 protein in 60% of the colorectal 
tumour specimens when compared to normal colonic mucosa. This could suggest that 
these patients are more likely to develop metastasis than patients whose tumour 
sample showed minimal or low expression of FGFR1 protein. 
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CHAPTER 6 
Discussion 
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The role of FGF-2 in solid cancers and in offering chemoresistance has drawn much 
interest among the researchers over the last decade. Pardo et al. investigated the role 
of FGF-2 on H510 SCLC cell line exposed to etoposide. They showed that a 
concentration of 0.1 ng/ml did not result in cellular proliferation and the cell numbers 
remained nearly the same in the FGF-2 treated and non-treated cells (228).  Our study 
demonstrated that a concentration of 0.25 ng/ml of FGF-2 resulted in similar effects 
on SW480 as well as SW620 colonic cancer cell lines. Netzer et al. studied the 
proliferative effects on HT-29 human colon cancer cell line using various 
concentrations of FGF-2 at the end of 96 hours by using the trypan blue exclusion 
method and showed that the cellular growth was stimulated in a dose dependent 
manner (257). This is comparable to our results which showed a similar dose 
dependent cellular proliferation both in SW480 and SW620 cell lines.  
 
It is intriguing as to why the FGF-2 mediated protection is observed in SW620 cell 
line but not in SW480 cell line, despite both these colonic adenocarcinoma cell lines 
being derived from the same patient. One explanation could be that addition of 
exogenous FGF-2 to SW620 metastatic adenocarcinoma cell line may result in 
binding and in turn activation of specific FGFR’s that results in cell survival through 
downstream signalling pathways such as the mitogen-activated Erk kinase (MEK)/ 
extracellular regulated kinase (Erk) and the phospotidylinositol 3-kinase (PI3K)/ 
protein kinase B (PKB) pathways. These signals have shown to influence survival 
through several mechanisms including the regulation of Bcl-2 and its family members. 
Similarly, the addition of FGF-2 in SW480 primary colonic adenocarcinoma cell line 
may not result in activation of these cell survival signalling pathways and possibly 
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trigger a cascade of cellular events that either downregulate anti-apoptotic or 
upregulate pro-apoptotic proteins thereby allowing the chemotherapeutic drugs to act 
and induce cellular apoptosis. Our studies have shown that both SW620 and SW480 
cell lines have a low basal expression of FGF-2 at a protein level; however addition 
of exogenous FGF-2 may trigger transcriptional upregulation of fgf2 in SW620 cells 
that could further result in caspase inactivation by upregulation of certain anti-
apoptotic proteins thereby blunting the apoptotic function of chemotherapy. There 
could indeed be many other complex intra-cellular mechanisms that may be triggered 
due to the addition of exogenous FGF-2 that give both these cell lines differential 
properties when exposed to chemotherapeutic agents. 
 
Pardo et al. demonstrated that FGF-2 resulted in translational but not transcriptional 
upregulation of Bcl-2 and Bcl-XL anti-apoptotic proteins in H510 SCLC cell line 
exposed to etoposide. This effect was not mediated by PI3 kinase/protein kinase B 
signalling as FGF-2 failed to activate this signalling pathway. In contrast, the 
mitogen-activated extracellularly regulated kinase (MEK) signalling pathway was 
crucial for this response because its inhibition abolished the pro-survival properties of 
FGF-2. They also showed that FGF-2 does not inhibit cytochrome-c release from 
mitochondria following etoposide treatment but does block Smac release and caspase 
activation (258). 
 
Although our studies did demonstrate FGF-2 mediated decrease in cellular apoptosis 
in SW620 cells exposed to 5-FU, we could not demonstrate any significant change in 
Bcl-2 or Bcl-XL either at a protein or gene level. We thus did not investigate the 
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intracellular signalling pathways, although these studies could have provided us with 
a better understanding of the complex intracellular signalling mechanisms in 
colorectal cell lines.   
 
FGF-2 is also known to regulate the expression of other apoptotic regulatory proteins 
such as IAPs. Addition of FGF-2 to cultures of endothelial cells induces the 
expression of survivin (188), and upregulation of survivin in endothelial cells is 
associated with protection from apoptosis induced by multiple chemotherapeutic 
agents (229). Western blot analysis has revealed that two members of the IAP family, 
XIAP and cIAP-1 are overexpressed in most small cell lung cancer cell lines, 
suggesting the possibility that these proteins play a role in the abberant protection of  
these cells from apoptosis. Addition of FGF-2 in H510 SCLC cell line induced a 
further increase in both XIAP and cIAP-1 expression in a time dependent fashion, up 
to four-fold at 4 hours following addition of FGF-2. This increase in XIAP and c-
IAP-1 protein levels was blocked using PD98059, an inhibitor of MEK/ERK pathway, 
suggesting that activation of MEK/ERK pathway is again necessary for this FGF-2 
induced effect. These results suggest a possible involvement of these IAPs in the pro-
survival activity of FGF-2. The role of IAPs in offering chemoprotection to FGF-2 
treated SW620 colonic cancer cells exposed to 5-FU needs to be investigated further. 
 
Jang characterised expression of FGFR’s in human colorectal carcinoma cell lines 
including DLD-1, HCT116, HCT-8, SW1116, SW403, Colo320, HT-29, LS147T and 
SW480 by RT-PCR Southern Blot analysis to determine the inter-receptor 
143 
 
relationship in gene expression among the fgfr’s. They observed a reciprocal 
relationship in gene expression between the fgfr1 (IIIc) and fgfr3 (IIIb) in all cell lines 
except SW403 and no differences in fgfr2 and fgfr4 expression. They knocked down 
fgfr1 expression using a 21-nucleotide fgfr1 siRNA in HCT116 cells which 
endogenously express fgfr1 but not fgfr3. Their results showed a clear increase of 
fgfr3 expression with the decrease of endogenous fgfr1 expression over time after 
transfection (259). These findings have important implications as FGFR3 has been 
shown to transduce a different signal that either inhibits or stimulates cell 
proliferation depending on the cell type. The phenotype observed in transgenic and 
knockout mouse suggests that the dysregulation of FGFR3 could impair cell growth 
and differentiation (260;261). On the contrary, several studies using Baf3 cells 
system have indicated that FGFR1 is much better at producing mitogenic signals than 
FGFR3 (208;262-263). Jang et al. in order to evaluate the effect of fgfr3 by the 
decrease of fgfr1 on cell growth properties in HCT116 cells compared the cellular 
proliferation rates and in vitro clonogenic assays. Their results showed FGFR1 
siRNA treated HCT116 cells proliferated more slowly than nontreated HCT116 cells 
(control) or control siRNA treated HCT116 cells. fgfr3 transfected HCT116 cells 
were also impaired in their clonogenicity in vitro  when compared with vector-
transfected HCT116 cells (control), which formed colonies in soft agar with high 
efficiency. These findings suggest that fgfr1 may confer a selective advantage on 
clones of cells in colorectal tumourigenesis, favouring proliferation, whereas fgfr3 
may have the effect of an unfavourable negative regulation of progression of the 
carcinomas to malignancy, promoting differentiation. Although quantitative RT-PCR 
studies carried out by us demonstrated variable expression of fgfrs in CRC tissue and 
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their corresponding normal colonic mucosa, our immunohistochemistry studies 
demonstrated significant upregulation of FGFR1 protein in CRC tissue samples when 
compared to normal colonic mucosa. Thus based on Jang’s findings, the increased 
expression of fgfr1 in CRC tissue samples may play an important role in tumour 
proliferation and colorectal tumourigenesis. This also has therapeutic implications 
and knockdown of fgfr1 by siRNA in colorectal tumours that have increased 
expression of this receptor, may either suppress tumour proliferation or result in 
overexpression of fgfr3 that may in turn arrest tumour growth and progression. 
  
George ML et al. (233) studied plasma FGF-2 levels in 124 CRC patients (87 
underwent surgery, 19 received pre-operative chemo-radiotherapy and out of the 18 
patients with distant metastases, 11 had chemotherapy and 7 had supportive care 
only), 26 patients with polyp and 55 healthy controls. Their study demonstrated 
significant difference in plasma FGF-2 levels between normal controls [median 4.14 
pg/ml (1.62-9.38 interquartile range)]  and all patients with CRC (Dukes stage A-D) 
[median 5.63pg/ml (2.85-13.19 interquartile range), p=0.018]. They also 
demonstrated significant increase in plasma FGF-2 levels in metastatic CRC patients 
(Dukes stage C and D) compared with polyp and non-metastatic cancer patients 
(p=0.0034 and 0.0023 respectively) and no difference between control, patients with 
polyp and those with Dukes stage A or B suggesting that no changes in the FGF-2 
levels occur during the transformation of a colonic adenoma into a carcinoma; the so 
called adenoma-colon carcinoma sequence. 
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A significant fall in serum FGF-2, 12 months following resection of the primary 
colorectal tumour in 48 disease free patients suggested that the tumour is responsible 
for the over-production of FGF-2, and that falling levels may be taken as an indicator 
for disease control (233). Similar observations were made by Dirix et al. (234) in 
serum levels of FGF-2 and VEGF in 14 operable colon cancer patients. The majority 
of patients with elevated preoperative FGF-2 or VEGF levels had a significantly low 
postoperative level of FGF-2 (p<0.05) levels and non-significant low levels of serum 
VEGF, 1 month after surgery (p=0.1). 
Although our results showed variable expression of FGF-2 in the serum of patients 
with operable CRC, there was expression of FGF-2 in all patients with metastatic 
CRC. A possible explanation for variable expression could be that the ELISA kit used 
by us to detect FGF-2 was not sensitive enough to detect levels below 0.5 pg/ml. The 
other limitations of our study was that we i) estimated serum FGF-2 levels in only a 
small number of patient’s, ii) did not estimate serum FGF-2 levels in healthy control 
patients to see if there was any change in basal FGF-2 levels between the two groups 
and also iii) did not estimate levels after surgical resection of CRC in these patients. 
Future studies that include a larger number of patients and incorporates the above 
mentioned points can help validate and confirm if serial assessment of circulating 
FGF-2 could help identify patients who develop disease progression during the 
course of chemotherapy and in turn predict response to treatment.  
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